{ "$schema_version": "5.4", "review_mode": "revision", "provenance_header": { "sources_total": 17, "claims_total": 21, "claims_verified": 21, "claims_unverified": 0, "claims_contradicted": 0, "tier_a_sources": 12, "generated_by": "HSEF v5.4; input grading by HSEF Review Agent v5.0 (OpenAI Codex environment), 2026-09-27; red-team synthesis by Claude (Anthropic), independent model, 2026-09-27; validator 2.4", "gate_passed": true }, "claims": [ { "id": "C1", "text": "A systematic umbrella review of six areas of serotonin research concluded that there is no convincing evidence that depression is associated with, or caused by, lower serotonin concentrations or activity.", "carries_number": false, "load_bearing_for": [ "SC1" ], "source_ns": [ 1 ], "verification": "verified", "verified_against": "full text", "verified_on": "2026-09-27", "note": "Verbatim conclusion of the Discussion section, confirmed in PMC10618090." }, { "id": "C2", "text": "That same umbrella review reports that tryptophan-depletion studies showed no effect in most healthy volunteers, weak evidence of an effect in volunteers with a family history of depression which it rated very low certainty, and slightly greater mood reduction in participants diagnosed with depression, most of whom had taken or were taking antidepressants.", "carries_number": false, "load_bearing_for": [ "SC1", "SC4" ], "source_ns": [ 1 ], "verification": "verified", "verified_against": "full text", "verified_on": "2026-09-27", "note": "Depletion-studies and Overall-results sections, PMC10618090." }, { "id": "C3", "text": "A meta-analysis of monoamine depletion studies found that depletion did not decrease mood in healthy controls, slightly lowered mood in healthy controls with a family history of major depressive disorder, produced a moderate mood decrease in drug-free patients with major depressive disorder in remission, and induced relapse in remitted patients taking serotonergic antidepressants; its authors concluded that depletion studies fail to demonstrate a causal relation and presumably clarify a vulnerability trait.", "carries_number": false, "load_bearing_for": [ "SC1", "SC4" ], "source_ns": [ 4 ], "verification": "verified", "verified_against": "abstract", "verified_on": "2026-09-27", "note": "All four strata and the causal-inference caveat are stated in the abstract of PMID 17389902." }, { "id": "C4", "text": "For the drug-free remitted-MDD stratum of that depletion meta-analysis, a published critique reports a pooled effect on mood of Hedges' g = -1.9 (95% CI -3.02 to -0.78) across 8 samples, falling to g = -1.06 (95% CI -1.83 to -0.29) when one potential outlier is removed.", "carries_number": true, "load_bearing_for": [ "SC4" ], "source_ns": [ 4, 2 ], "verification": "verified", "verified_against": "full text", "verified_on": "2026-09-27", "note": "Figures read in the full text of the critique (PMC10618084), which attributes them to the meta-analysis it is criticising; not independently re-read in that meta-analysis's own full text, which is paywalled. The critique describes this stratum as 'depressed people not taking antidepressants'; the meta-analysis's own abstract describes it as drug-free patients with MDD in remission." }, { "id": "C5", "text": "In a double-blind, placebo-controlled crossover study of 21 patients in antidepressant-induced remission, total and free plasma tryptophan fell 87% and 91% during acute depletion, 14 of the 21 patients relapsed, and mood returned to the remitted state within 24 to 48 hours of resuming normal food intake, while control testing produced no significant behavioural effect.", "carries_number": true, "load_bearing_for": [ "SC3", "SC4" ], "source_ns": [ 5 ], "verification": "verified", "verified_against": "abstract", "verified_on": "2026-09-27", "note": "All figures stated in the abstract of PMID 2184795. The study had no healthy-control and no drug-naive arm; its comparator was sham depletion in the same patients." }, { "id": "C6", "text": "In a positron emission tomography study using a serotonin 5-HT2A agonist radioligand with a d-amphetamine challenge, frontal binding fell significantly in 20 healthy control subjects but not in 17 antidepressant-free patients in a major depressive episode, the change being smaller in the patient group (15% plus or minus 14% versus 6.5% plus or minus 20%, p = 0.041).", "carries_number": true, "load_bearing_for": [ "SC1" ], "source_ns": [ 6 ], "verification": "verified", "verified_against": "abstract", "verified_on": "2026-09-27", "note": "Group sizes, percentage changes and p value stated in the abstract of PMID 36635177. The endpoint is a receptor-binding measure, not symptom trajectory." }, { "id": "C7", "text": "A collaborative meta-analysis applying a uniform analysis to 31 datasets and 38,802 subjects found no subgroup or variable definition for which an interaction between stress and 5-HTTLPR genotype was statistically significant.", "carries_number": true, "load_bearing_for": [ "SC1" ], "source_ns": [ 7 ], "verification": "verified", "verified_against": "abstract", "verified_on": "2026-09-27", "note": "Dataset count, sample size and null result stated in the abstract of PMID 28373689." }, { "id": "C8", "text": "An analysis of 18 historical depression candidate genes in samples ranging from 62,138 to 443,264 individuals found no clear evidence of polymorphism main effects or polymorphism-by-environment interactions, and found that candidate genes as a set were no more associated with depression phenotypes than non-candidate genes.", "carries_number": true, "load_bearing_for": [ "SC1" ], "source_ns": [ 8 ], "verification": "verified", "verified_against": "abstract", "verified_on": "2026-09-27", "note": "Gene count, sample range and null result stated in the abstract of PMID 30845820." }, { "id": "C9", "text": "A network meta-analysis of 522 double-blind randomised trials comprising 116,477 participants found all 21 antidepressants studied more efficacious than placebo, with odds ratios ranging from 2.13 (95% credible interval 1.89-2.41) for amitriptyline to 1.37 (1.16-1.63) for reboxetine; 46 of the 522 trials were rated at high risk of bias and the certainty of evidence was moderate to very low.", "carries_number": true, "load_bearing_for": [ "SC2" ], "source_ns": [ 9 ], "verification": "verified", "verified_against": "abstract", "verified_on": "2026-09-27", "note": "Trial and participant counts, odds ratios, risk-of-bias tally and GRADE statement all in the abstract of PMID 29477251." }, { "id": "C10", "text": "In 35 registration trials of four new-generation antidepressants submitted to the US Food and Drug Administration, comprising 5,133 patients, weighted mean improvement was 9.60 Hamilton Rating Scale for Depression points on drug and 7.80 on placebo, a difference of 1.80 points or a standardised mean difference of 0.32; the difference met the three-point criterion adopted by NICE only in trials whose mean baseline score exceeded about 28, and the widening difference was attributable to a decrease in placebo response rather than an increase in drug response.", "carries_number": true, "load_bearing_for": [ "SC2" ], "source_ns": [ 10 ], "verification": "verified", "verified_against": "full text", "verified_on": "2026-09-27", "note": "Results section of PMC2253608 (trial and patient counts, 9.60 versus 7.80, d = 1.24 versus 0.92, difference 0.32, baseline threshold of about 28)." }, { "id": "C11", "text": "A systematic review with meta-analysis and Trial Sequential Analysis that included 131 placebo-controlled SSRI trials in 27,422 participants found a mean difference of -1.94 Hamilton Depression Rating Scale points, pooled over the 49 of those trials reporting the outcome (95% CI -2.50 to -1.37) in favour of SSRIs, below the reviewers' pre-defined three-point threshold for clinical significance; none of the included trials used an active placebo or a no-intervention control, and all were judged to be at high risk of bias.", "carries_number": true, "load_bearing_for": [ "SC2" ], "source_ns": [ 11 ], "verification": "verified", "verified_against": "abstract", "verified_on": "2026-09-27", "note": "Trial and participant counts, effect estimate, threshold, absence of active-placebo controls and risk-of-bias judgement all stated in the abstract of PMID 28178949." }, { "id": "C12", "text": "A Cochrane review of nine trials comparing antidepressants with active placebos in 751 participants found a pooled effect on mood of 0.39 standard deviations (95% CI 0.24 to 0.54), falling to 0.17 (0.00 to 0.34) when one strongly positive trial was omitted, and its authors concluded that unblinding effects may inflate the apparent efficacy of antidepressants in trials using inert placebos.", "carries_number": true, "load_bearing_for": [ "SC2" ], "source_ns": [ 12 ], "verification": "verified", "verified_against": "abstract", "verified_on": "2026-09-27", "note": "Study and participant counts, both pooled estimates and the unblinding conclusion are stated in the abstract of PMID 14974002. The included trials are predominantly tricyclic-versus-atropine comparisons rather than SSRI trials." }, { "id": "C13", "text": "A patient-level, item-based post-hoc analysis pooling 8,262 participants from 28 placebo-controlled SSRI trials found that patients with non-severe and with severe depression did not differ in the SSRI-induced reduction of depressed mood or of the other items of the six-item Hamilton subscale, the apparent dependence on baseline severity arising when the 17-item sum score was used as the outcome.", "carries_number": true, "load_bearing_for": [ "SC2" ], "source_ns": [ 13 ], "verification": "verified", "verified_against": "abstract", "verified_on": "2026-09-27", "note": "Participant and trial counts, the subscale result and the interpretation are stated in the abstract of PMID 31303567." }, { "id": "C14", "text": "A review of antidepressant mechanism argues that the delayed clinical onset of antidepressants is not explained by acute monoamine potentiation and advances neuroplasticity and early change in negative affective bias as candidate mechanisms, while stating that all currently licensed antidepressants are believed to relieve depression by increasing serotonin or norepinephrine availability, or both, at least initially.", "carries_number": false, "load_bearing_for": [ "SC3" ], "source_ns": [ 14 ], "verification": "verified", "verified_against": "full text", "verified_on": "2026-09-27", "note": "Both positions are in the full text of PMC5410405; the second is a verbatim statement in the 'Current pharmacological treatment approaches' section." }, { "id": "C15", "text": "The same review reports that early drug-induced change in emotional processing predicts later clinical response, and argues that this drug-induced variation is a specific treatment effect rather than a general mediator of placebo response or expectation.", "carries_number": false, "load_bearing_for": [ "SC2", "SC3" ], "source_ns": [ 14 ], "verification": "verified", "verified_against": "full text", "verified_on": "2026-09-27", "note": "'Prediction of clinical action' section, PMC5410405." }, { "id": "C16", "text": "A content analysis of direct-to-consumer SSRI advertising found that advertisements claiming antidepressants correct a serotonin imbalance were not supported by the peer-reviewed scientific literature.", "carries_number": false, "load_bearing_for": [ "SC3" ], "source_ns": [ 15 ], "verification": "verified", "verified_against": "abstract", "verified_on": "2026-09-27", "note": "Abstract and framing of PMID 16268734." }, { "id": "C17", "text": "The umbrella review reports that principal English-language textbooks still give the serotonin theory qualified support, that surveys indicate most of the general public believes it is established that depression is caused by a chemical imbalance, and that many general practitioners share that view.", "carries_number": false, "load_bearing_for": [], "source_ns": [ 1 ], "verification": "verified", "verified_against": "full text", "verified_on": "2026-09-27", "note": "Introduction and Discussion sections, PMC10618090. Registered as the basis for the Divergence arithmetic, which is a claim about how the field presents itself and is therefore appropriately carried by a review." }, { "id": "C18", "text": "In a survey of 1,219 college students, the most commonly reported sources of the chemical-imbalance explanation were the classroom, the internet and media, other people, and healthcare providers, and only having heard it from a healthcare provider uniquely predicted endorsing the belief after adjustment.", "carries_number": true, "load_bearing_for": [], "source_ns": [ 16 ], "verification": "verified", "verified_against": "abstract", "verified_on": "2026-09-27", "note": "Sample size, source ranking and regression result stated in the abstract of PMID 39845538. Registered as a Divergence artifact." }, { "id": "C19", "text": "In reply to the published critique, the umbrella review's authors maintained their conclusion that the main areas of serotonin research do not support the serotonin theory of depression.", "carries_number": false, "load_bearing_for": [], "source_ns": [ 3 ], "verification": "verified", "verified_against": "full text", "verified_on": "2026-09-27", "note": "Accessible portion of the correspondence at the publisher page. Registered so that the dissent in the literature is recorded rather than summarised only from one side." }, { "id": "C20", "text": "A multi-author published critique argues that the umbrella review's conclusion is overstated, citing selective reporting of the depletion literature, omission of meta-analyses of circulating tryptophan, and over-simplified interpretation of 5-HT1A and serotonin-transporter imaging, and concludes that depletion and imaging findings indicate a role for serotonin in people vulnerable to or suffering from depression.", "carries_number": false, "load_bearing_for": [ "SC1" ], "source_ns": [ 2 ], "verification": "verified", "verified_against": "full text", "verified_on": "2026-09-27", "note": "Full text of PMC10618084." }, { "id": "C21", "text": "A meta-analysis of 26 prospective studies of interferon-alpha therapy for chronic hepatitis C in patients free of a depressive episode at baseline estimated a cumulative incidence of induced major depressive episode of 0.25 (95% CI 0.16 to 0.35) at 24 weeks and 0.28 (0.17 to 0.42) at 48 weeks.", "carries_number": true, "load_bearing_for": [], "source_ns": [ 17 ], "verification": "verified", "verified_against": "abstract", "verified_on": "2026-09-27", "note": "Study count, incidence estimates and confidence intervals stated in the abstract of PMID 22967776. Registered for the competing-model tournament." } ], "citation_ledger": [ { "n": 1, "citation": "Moncrieff J, Cooper RE, Stockmann T, Amendola S, Hengartner MP, Horowitz MA. The serotonin theory of depression: a systematic umbrella review of the evidence. Mol Psychiatry. 2023;28(8):3243-3256.", "tier": "B", "kind": "review", "pmid": "35854107", "doi": "10.1038/s41380-022-01661-0", "url": "https://pubmed.ncbi.nlm.nih.gov/35854107/", "status_flags": [ "none_found" ], "carries_claims": [ "C1", "C2", "C17" ], "opened": true, "opened_on": "2026-09-27", "status_checked_on": "2026-09-27", "study_id": "MONCRIEFF-2022-UMBRELLA", "access_depth": "full_text_complete", "access_note": "Full text read via PMC10618090, including the depletion-studies and overall-results sections. Record is indexed with a 2022 electronic publication date and a 2023 issue; the issue citation is used here." }, { "n": 2, "citation": "Jauhar S, Arnone D, Baldwin DS, Bloomfield M, Browning M, Cleare AJ, et al. A leaky umbrella has little value: evidence clearly indicates the serotonin system is implicated in depression. Mol Psychiatry. 2023;28(8):3149-3152.", "tier": "B", "kind": "review", "pmid": "37322065", "doi": "10.1038/s41380-023-02095-y", "url": "https://pubmed.ncbi.nlm.nih.gov/37322065/", "status_flags": [ "none_found" ], "carries_claims": [ "C4", "C20" ], "opened": true, "opened_on": "2026-09-27", "status_checked_on": "2026-09-27", "study_id": "JAUHAR-2023-COMMENT", "access_depth": "full_text_complete", "access_note": "Full text read via PMC10618084. Published comment on source 1." }, { "n": 3, "citation": "Moncrieff J, Cooper RE, Stockmann T, Amendola S, Hengartner MP, Ploderl M, Horowitz MA. The serotonin hypothesis of depression: both long discarded and still supported? Mol Psychiatry. 2023;28(8):3160-3163.", "tier": "B", "kind": "review", "pmid": "37322064", "doi": "10.1038/s41380-023-02094-z", "url": "https://pubmed.ncbi.nlm.nih.gov/37322064/", "status_flags": [ "none_found" ], "carries_claims": [ "C19" ], "opened": true, "opened_on": "2026-09-27", "status_checked_on": "2026-09-27", "study_id": "MONCRIEFF-2023-REPLY", "access_depth": "full_text_partial", "access_note": "Publisher page; the accessible portion of the correspondence only. No PubMed abstract exists for this letter. Used for a single non-numeric claim about the authors' stated position." }, { "n": 4, "citation": "Ruhe HG, Mason NS, Schene AH. Mood is indirectly related to serotonin, norepinephrine and dopamine levels in humans: a meta-analysis of monoamine depletion studies. Mol Psychiatry. 2007;12(4):331-359.", "tier": "A", "kind": "meta_analysis", "pmid": "17389902", "doi": "10.1038/sj.mp.4001949", "url": "https://pubmed.ncbi.nlm.nih.gov/17389902/", "status_flags": [ "none_found" ], "carries_claims": [ "C3", "C4" ], "opened": true, "opened_on": "2026-09-27", "status_checked_on": "2026-09-27", "study_id": "RUHE-2007-DEPLETION", "access_depth": "abstract_metadata", "access_note": "Abstract and PubMed record; full text is behind a paywall and was not read. The subgroup effect size in C4 is taken from source 2, which reports it from this meta-analysis." }, { "n": 5, "citation": "Delgado PL, Charney DS, Price LH, Aghajanian GK, Landis H, Heninger GR. Serotonin function and the mechanism of antidepressant action. Reversal of antidepressant-induced remission by rapid depletion of plasma tryptophan. Arch Gen Psychiatry. 1990;47(5):411-418.", "tier": "A", "kind": "primary", "pmid": "2184795", "doi": "10.1001/archpsyc.1990.01810170011002", "url": "https://pubmed.ncbi.nlm.nih.gov/2184795/", "status_flags": [ "none_found" ], "carries_claims": [ "C5" ], "opened": true, "opened_on": "2026-09-27", "status_checked_on": "2026-09-27", "study_id": "DELGADO-1990-ATD", "access_depth": "abstract_metadata", "access_note": "Abstract and PubMed record; no PMC full text." }, { "n": 6, "citation": "Erritzoe D, Godlewska BR, Rizzo G, Searle GE, Agnorelli C, Lewis Y, et al. Brain serotonin release is reduced in patients with depression: a [11C]Cimbi-36 positron emission tomography study with a d-amphetamine challenge. Biol Psychiatry. 2023;93(12):1089-1098.", "tier": "A", "kind": "primary", "pmid": "36635177", "doi": "10.1016/j.biopsych.2022.10.012", "url": "https://pubmed.ncbi.nlm.nih.gov/36635177/", "status_flags": [ "none_found" ], "carries_claims": [ "C6" ], "opened": true, "opened_on": "2026-09-27", "status_checked_on": "2026-09-27", "study_id": "ERRITZOE-2023-CIMBI36", "access_depth": "abstract_metadata", "access_note": "Abstract and PubMed record; no PMC full text." }, { "n": 7, "citation": "Culverhouse RC, Saccone NL, Horton AC, Ma Y, Anstey KJ, Banaschewski T, et al. Collaborative meta-analysis finds no evidence of a strong interaction between stress and 5-HTTLPR genotype contributing to the development of depression. Mol Psychiatry. 2018;23(1):133-142.", "tier": "A", "kind": "meta_analysis", "pmid": "28373689", "doi": "10.1038/mp.2017.44", "url": "https://pubmed.ncbi.nlm.nih.gov/28373689/", "status_flags": [ "none_found" ], "carries_claims": [ "C7" ], "opened": true, "opened_on": "2026-09-27", "status_checked_on": "2026-09-27", "study_id": "CULVERHOUSE-2018-5HTTLPR", "access_depth": "abstract_metadata", "access_note": "Abstract and PubMed record. Tiered A because the consortium executed a uniform analysis script on primary data rather than pooling published summaries." }, { "n": 8, "citation": "Border R, Johnson EC, Evans LM, Smolen A, Berley N, Sullivan PF, Keller MC. No support for historical candidate gene or candidate gene-by-interaction hypotheses for major depression across multiple large samples. Am J Psychiatry. 2019;176(5):376-387.", "tier": "A", "kind": "primary", "pmid": "30845820", "doi": "10.1176/appi.ajp.2018.18070881", "url": "https://pubmed.ncbi.nlm.nih.gov/30845820/", "status_flags": [ "none_found" ], "carries_claims": [ "C8" ], "opened": true, "opened_on": "2026-09-27", "status_checked_on": "2026-09-27", "study_id": "BORDER-2019-CANDIDATEGENE", "access_depth": "abstract_metadata", "access_note": "Abstract and PubMed record." }, { "n": 9, "citation": "Cipriani A, Furukawa TA, Salanti G, Chaimani A, Atkinson LZ, Ogawa Y, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet. 2018;391(10128):1357-1366.", "tier": "A", "kind": "meta_analysis", "pmid": "29477251", "doi": "10.1016/S0140-6736(17)32802-7", "url": "https://pubmed.ncbi.nlm.nih.gov/29477251/", "status_flags": [ "none_found" ], "carries_claims": [ "C9" ], "opened": true, "opened_on": "2026-09-27", "status_checked_on": "2026-09-27", "study_id": "CIPRIANI-2018-NMA", "access_depth": "abstract_metadata", "access_note": "Abstract and PubMed record; the pooled odds ratios, trial and participant counts and risk-of-bias tallies cited here are all reported in the abstract." }, { "n": 10, "citation": "Kirsch I, Deacon BJ, Huedo-Medina TB, Scoboria A, Moore TJ, Johnson BT. Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. PLoS Med. 2008;5(2):e45.", "tier": "A", "kind": "meta_analysis", "pmid": "18303940", "doi": "10.1371/journal.pmed.0050045", "url": "https://pubmed.ncbi.nlm.nih.gov/18303940/", "status_flags": [ "none_found" ], "carries_claims": [ "C10" ], "opened": true, "opened_on": "2026-09-27", "status_checked_on": "2026-09-27", "study_id": "KIRSCH-2008-FDA", "access_depth": "full_text_complete", "access_note": "Full text read via PMC2253608, including the Results section from which the improvement scores and the baseline-severity threshold are taken." }, { "n": 11, "citation": "Jakobsen JC, Katakam KK, Schou A, Hellmuth SG, Stallknecht SE, Leth-Moller K, et al. Selective serotonin reuptake inhibitors versus placebo in patients with major depressive disorder. A systematic review with meta-analysis and Trial Sequential Analysis. BMC Psychiatry. 2017;17(1):58.", "tier": "A", "kind": "meta_analysis", "pmid": "28178949", "doi": "10.1186/s12888-016-1173-2", "url": "https://pubmed.ncbi.nlm.nih.gov/28178949/", "status_flags": [ "erratum: Jakobsen JC, et al. Erratum to: Selective serotonin reuptake inhibitors versus placebo in patients with major depressive disorder. BMC Psychiatry. 2017;17(1):162. PMID 28468655; doi:10.1186/s12888-017-1311-5" ], "carries_claims": [ "C11" ], "opened": true, "opened_on": "2026-09-27", "status_checked_on": "2026-09-27", "study_id": "JAKOBSEN-2017-SSRI", "access_depth": "abstract_metadata", "access_note": "Abstract and PubMed record. The erratum is attached here rather than given its own row." }, { "n": 12, "citation": "Moncrieff J, Wessely S, Hardy R. Active placebos versus antidepressants for depression. Cochrane Database Syst Rev. 2004;2004(1):CD003012.", "tier": "A", "kind": "meta_analysis", "pmid": "14974002", "doi": "10.1002/14651858.CD003012.pub2", "url": "https://pubmed.ncbi.nlm.nih.gov/14974002/", "status_flags": [ "none_found" ], "carries_claims": [ "C12" ], "opened": true, "opened_on": "2026-09-27", "status_checked_on": "2026-09-27", "study_id": "MONCRIEFF-2004-ACTIVEPLACEBO", "access_depth": "abstract_metadata", "access_note": "Abstract and PubMed record; the pooled estimates and the sensitivity analysis are reported there." }, { "n": 13, "citation": "Hieronymus F, Lisinski A, Nilsson S, Eriksson E. Influence of baseline severity on the effects of SSRIs in depression: an item-based, patient-level post-hoc analysis. Lancet Psychiatry. 2019;6(9):745-752.", "tier": "A", "kind": "primary", "pmid": "31303567", "doi": "10.1016/S2215-0366(19)30216-0", "url": "https://pubmed.ncbi.nlm.nih.gov/31303567/", "status_flags": [ "none_found" ], "carries_claims": [ "C13" ], "opened": true, "opened_on": "2026-09-27", "status_checked_on": "2026-09-27", "study_id": "HIERONYMUS-2019-ITEMLEVEL", "access_depth": "abstract_metadata", "access_note": "Abstract and PubMed record." }, { "n": 14, "citation": "Harmer CJ, Duman RS, Cowen PJ. How do antidepressants work? New perspectives for refining future treatment approaches. Lancet Psychiatry. 2017;4(5):409-418.", "tier": "B", "kind": "review", "pmid": "28153641", "doi": "10.1016/S2215-0366(17)30015-9", "url": "https://pubmed.ncbi.nlm.nih.gov/28153641/", "status_flags": [ "none_found" ], "carries_claims": [ "C14", "C15" ], "opened": true, "opened_on": "2026-09-27", "status_checked_on": "2026-09-27", "study_id": "HARMER-2017-MECHANISM", "access_depth": "full_text_complete", "access_note": "Full text read via PMC5410405." }, { "n": 15, "citation": "Lacasse JR, Leo J. Serotonin and depression: a disconnect between the advertisements and the scientific literature. PLoS Med. 2005;2(12):e392.", "tier": "B", "kind": "review", "pmid": "16268734", "doi": "10.1371/journal.pmed.0020392", "url": "https://pubmed.ncbi.nlm.nih.gov/16268734/", "status_flags": [ "none_found" ], "carries_claims": [ "C16" ], "opened": true, "opened_on": "2026-09-27", "status_checked_on": "2026-09-27", "study_id": "LACASSE-2005-ADVERTISEMENTS", "access_depth": "abstract_metadata", "access_note": "Abstract and PubMed record." }, { "n": 16, "citation": "Schroder HS, Tovey J, Forer R, Schultz W, Kneeland ET, Moser JS. Where do “chemical imbalance” beliefs come from? Evaluating the impact of different sources. Front Psychol. 2025;15:1469913.", "tier": "A", "kind": "primary", "pmid": "39845538", "doi": "10.3389/fpsyg.2024.1469913", "url": "https://pubmed.ncbi.nlm.nih.gov/39845538/", "status_flags": [ "none_found" ], "carries_claims": [ "C18" ], "opened": true, "opened_on": "2026-09-27", "status_checked_on": "2026-09-27", "study_id": "SCHRODER-2025-BELIEFS", "access_depth": "abstract_metadata", "access_note": "Abstract and PubMed record." }, { "n": 17, "citation": "Udina M, Castellvi P, Moreno-Espana J, Navines R, Valdes M, Forns X, et al. Interferon-induced depression in chronic hepatitis C: a systematic review and meta-analysis. J Clin Psychiatry. 2012;73(8):1128-1138.", "tier": "A", "kind": "meta_analysis", "pmid": "22967776", "doi": "10.4088/JCP.12r07694", "url": "https://pubmed.ncbi.nlm.nih.gov/22967776/", "status_flags": [ "none_found" ], "carries_claims": [ "C21" ], "opened": true, "opened_on": "2026-09-27", "status_checked_on": "2026-09-27", "study_id": "UDINA-2012-IFN", "access_depth": "abstract_metadata", "access_note": "Abstract and PubMed record. Used only for the competing-model tournament." } ], "claim_restatement": { "index_wording": "not in corpus index; fresh entry - serotonin deficiency hypothesis for major depressive disorder", "entry_form": "conjunction", "gradeable_restatement": "Deficient serotonin neurotransmission is a proximate cause of major depressive disorder, and SSRIs relieve major depressive disorder by correcting that serotonin deficit.", "restatement_required": true, "split_into": [ "SC1", "SC2", "SC3", "SC4" ], "parent_claim": null, "scope_qualifiers": [ { "qualifier": "major depressive disorder", "determinable_before_outcome": true, "determined_from": "baseline diagnostic status by DSM criteria at enrollment", "action": "retained" }, { "qualifier": "in people with a history of major depressive disorder (SC4 only)", "determinable_before_outcome": true, "determined_from": "documented past episode and current remission status at enrollment", "action": "retained" }, { "qualifier": "in responders", "determinable_before_outcome": false, "determined_from": "response to treatment, which is the assessed outcome", "action": "deleted" } ] }, "lay_summary": { "paragraphs": [ "For decades the most familiar explanation of depression has been that it is caused by too little of a brain chemical called serotonin, and that the antidepressant pills known as SSRIs work by topping that chemical back up. This review asks how much of that explanation the scientific evidence actually supports.", "The short answer is: the mechanism is plausible and partly supported in simplified settings, but the central claim has not been demonstrated in people. Large reviews have not found that people who are depressed reliably have less serotonin than people who are not, and the genetic studies that were supposed to link the serotonin system to depression have failed in very large samples. What has been shown is narrower and real: in people who have been depressed before, an experiment that temporarily strips the body of the raw material for making serotonin can bring symptoms back, and can reverse a recovery achieved on medication. The same experiment does nothing to the mood of people who have never been depressed. SSRIs do outperform dummy pills on average, but the difference is small, and no trial has compared an SSRI against a dummy pill designed to mimic its side effects while checking whether patients could tell which one they were taking.", "So the grade here is one step above a bare association: the evidence establishes a plausible mechanism with partial support, not a demonstrated cause. A grade like this is a statement about which experiments have and have not been done, not an accusation against any researcher, and it is not a claim that antidepressants do not work. It would move up if a properly blinded trial with a matched comparator showed the drug effect survives, or if an experiment could separate correcting a shortage from simply pushing the system in one direction." ], "grade_restated_faithfully": true, "claims_referenced": [ "C1", "C3", "C5", "C7", "C8", "C9", "C11", "C12" ], "jargon_glossed": [ "serotonin", "SSRI", "placebo", "tryptophan depletion", "blinding" ], "no_practical_advice": true, "written_for": "general reader, no field background" }, "hypothesis": { "name": "Serotonin deficiency hypothesis of MDD", "central_claim": "Deficient serotonin neurotransmission causes MDD, and SSRIs relieve it by correcting that deficiency.", "proposed_mechanism": "Reduced 5-HT availability at postsynaptic receptors impairs mood regulation; SSRIs block the serotonin reuptake transporter to restore adequate 5-HT signalling, correcting the deficiency.", "claimed_scope": "disease-class", "claimed_level": [ "initiation", "maintenance", "response" ], "is_conjunctive": true, "conjunctive_note": "The clause nobody has isolated is 'by correcting that deficit'. Serotonin availability HAS been manipulated in humans with the drug left in place - acute tryptophan depletion reverses antidepressant-induced remission - but that manipulation tests whether the drug response depends on serotonin, not whether a pre-existing deficit was corrected. No experiment distinguishes correction of a prior deficit from pharmacological displacement of a system that was not deficient." }, "rubric_routing": { "primary_rubric": "07-psychiatry-neuromodulation.md", "secondary_rubrics": [], "index_notes_applied": [], "rubric_fit_note": "Good fit; the rubric's scope names 'antidepressant mechanism claims (monoamine, neuroplasticity, neuroinflammation)' and 'the monoamine hypothesis' explicitly. The hypothesis index carries no entry for this hypothesis, so no index note overrides generic rubric behaviour; the two 'index adjudication notes' recorded in the input grading do not appear in hypothesis-index.md and were not applied here. A stub index entry is recommended in the reviewer notes." }, "subclaim_matrix": { "subclaims": [ { "id": "SC1", "statement": "Deficient serotonin neurotransmission is a proximate cause of the initiation or maintenance of major depressive disorder.", "subclaim_type": "primacy", "governing_rubric": "07-psychiatry-neuromodulation.md", "scope": "adults meeting DSM criteria for major depressive disorder; disease-class claim about initiation and maintenance", "claimed_scope": "disease-class", "key_evidence_anchor": "A blinded depletion or challenge experiment in drug-naive people with a current depressive episode, or in never-depressed volunteers, whose outcome is symptom trajectory", "hsef_level": "Γ", "confidence": "Moderate", "governing_cap_or_threshold": "Rubric 07 Γ cap - 'Mechanistic plausibility with in vitro, rodent, or unblinded human support caps at Γ' - together with boundary-check clause 5: the qualifying human depletion experiment returns no mood effect in most healthy volunteers (C2, C3), so Δ is not crossed.", "rationale": "The deficiency premise itself is unsupported: the largest synthesis finds no consistent evidence of lowered serotonin in depression (C1), and the genetic leg is null in the two largest and highest-quality studies (C7, C8). The subclaim is nonetheless not association-only, which is what Β describes: it rests additionally on a human depletion-challenge programme (C3), on an unblinded human pharmacological challenge (C6), and on the pharmacology of the drugs themselves (C14), which is what the rubric's Γ cap governs through its 'unblinded human support' limb. No rodent evidence is relied on. Universal cap 2 binds the biomarker and genetic leg and prevents that leg from carrying the subclaim past Β on its own; it does not set the ceiling for a subclaim whose base also contains human perturbation (pitfall 21)." }, { "id": "SC2", "statement": "SSRIs relieve the symptoms of major depressive disorder to a greater extent than placebo.", "subclaim_type": "existence", "governing_rubric": "07-psychiatry-neuromodulation.md", "scope": "adults with major depressive disorder in short-term randomised placebo-controlled trials", "claimed_scope": "disease-class", "key_evidence_anchor": "An SSRI trial against a comparator matched for acute subjective effect, with blinding integrity measured and reported", "hsef_level": "Γ", "confidence": "High", "governing_cap_or_threshold": "The rubric's Δ threshold is not met: it 'Requires a controlled human interventional study with a credible active comparator, or a mediator manipulation in humans, with a pre-registered primary outcome', and no SSRI trial with a comparator matched for acute subjective effect and measured blinding integrity exists (C11, C12).", "rationale": "The effect is real and among the most replicated results in psychiatry (C9), though small on the sum score and of contested clinical importance (C10, C11), and its dependence on baseline severity is itself contested at patient level (C13). What is missing is not evidence of an effect but the comparator the rubric requires. The nearest existing design - the active-placebo trials - is 'partially matched' and therefore Moderate evidence in this rubric, and its pooled effect falls to 0.17 (0.00-0.34) when one trial is removed (C12). The word 'specifically' has been removed from this subclaim and returned to SC3, where the specificity question belongs." }, { "id": "SC3", "statement": "SSRIs relieve major depressive disorder specifically by correcting a pre-existing serotonin deficit rather than by any other mechanism.", "subclaim_type": "mechanism", "governing_rubric": "07-psychiatry-neuromodulation.md", "scope": "adults with major depressive disorder who respond to an SSRI; the mediating mechanism of that response", "claimed_scope": "mechanism", "key_evidence_anchor": "An experiment that separates correction of a pre-existing deficit from pharmacological elevation in a system that was not deficient - for example, response stratified by an independently measured baseline serotonin index", "hsef_level": "Γ", "confidence": "Moderate", "governing_cap_or_threshold": "Rubric 07 Γ cap, with Δ not crossed: the available mediator manipulation (C3, C5) tests whether the drug response depends on serotonin availability, not whether a pre-existing deficit was corrected, and the deficit premise fails at SC1.", "rationale": "The mediator has been manipulated, so the rubric's mediation-by-correlation rule - 'Candidate mediator correlated with outcome, never manipulated' - does not fire, contrary to the input grading. What blocks Δ is that the manipulation answers a different question. Depletion reversing a drug-induced remission (C5) is equally consistent with a system pushed above its baseline by a drug and with restoration of a prior deficit; nothing measured distinguishes them. Rival mediators with prospective predictive support exist (C14, C15)." }, { "id": "SC4", "statement": "Serotonin availability is causally required to maintain the recovered state in people with a history of major depressive disorder.", "subclaim_type": "necessity", "governing_rubric": "07-psychiatry-neuromodulation.md", "scope": "adults with a documented history of major depressive disorder who are currently in remission, whether drug-free or maintained on a serotonergic antidepressant", "claimed_scope": "context-specific", "key_evidence_anchor": "A pre-registered, blinded depletion experiment in remitted patients with a serotonin-specific manipulation check, replicated by an independent group", "hsef_level": "Δ", "confidence": "Moderate", "governing_cap_or_threshold": "Δ threshold crossed on the rubric's field-valid perturbation 'Depletion or challenge experiment in humans whose outcome is symptom trajectory, not a biomarker', with a positive result (C3, C4, C5). Ε not reached: the context boundary is suggested but not cleanly mapped.", "rationale": "This is the subclaim the input grading omitted, and it is where the hypothesis has its only positive human causal line. Acute tryptophan depletion is blinded, within-subject, leaves the intervention in place and reads out symptom trajectory; it reverses antidepressant-induced remission (C5) and lowers mood in drug-free remitted patients (C3, C4) while doing nothing to never-depressed volunteers (C2, C3). Confidence is held at Moderate, not High: several of the drug-free-remitted samples come from overlapping groups, the outlier sensitivity is large (C4), recent crossover studies in depressed patients were unconvincing (C2), and the manipulation's specificity for serotonin is contested (pitfall 11)." } ], "aggregation_rule": "weakest-link", "aggregation_preregistered": true, "aggregation_rationale": "Pre-registered for conjunctive claims: the graded claim joins a causation clause to a mechanism-of-treatment clause with an 'and', so the conjunction is only as strong as its weakest clause; the rule is carried over unchanged from the input grading, which pre-registered it before scoring.", "primary_subclaim_id": "", "aggregation_derivation": "Weakest-link over SC1=Γ, SC2=Γ, SC3=Γ, SC4=Δ gives Γ.", "aggregation_alternatives": { "weakest_link_would_return": "Γ", "primary_subclaim_would_return": "Γ", "scope_matched_would_return": "Γ", "note": "REQUIRED. All three rules now return Γ. Under primary-subclaim the primary is SC3, the mechanistic clause that supplies the hypothesis's distinguishing content, which is Γ. Under scope-matched the central claim's scope is disease-class, and the highest subclaim advanced at that scope is Γ (SC1 and SC2); SC4 is context-specific and is reported separately. The letter is therefore no longer rule-dependent, which was not true of the input grading, where weakest-link and scope-matched returned Β while primary-subclaim returned Γ." }, "index_rule_deviation": "" }, "competing_models": { "models_evaluated": [ { "rank_in_tournament": 1, "model_id": "M3", "is_nominal": false, "name": "Neuroinflammation hypothesis", "core_claim": "MDD is initiated and maintained by elevated peripheral and central inflammatory mediators, which dysregulate monoamine metabolism and impair neuroplasticity.", "explains_what_nominal_does_not": "Explains the comorbidity of depression with inflammatory illness, the emergence of depressive episodes in people given cytokines, and the poorer SSRI response reported in high-inflammation subgroups.", "strongest_supporting_evidence": [ "Pharmacological cytokine exposure in people who were free of a depressive episode at baseline is followed by incident major depressive episodes at a quantified rate (C21)", "Case-control meta-analyses of circulating inflammatory markers in depression" ], "strongest_contradictory_evidence": [ "Interferon-alpha is an exogenous pharmacological exposure, not the endogenous inflammatory state the model claims", "Anti-inflammatory treatment trials in unselected depression are mixed", "Inflammatory marker elevation is non-specific across many conditions" ], "hsef_level_for_this_model": "Γ", "rationale": "Ranks first because it has the strongest human causal line bearing on initiation: an exposure administered to people without depression is followed by incident episodes at a rate estimated from 26 prospective studies (C21). It caps at Γ nonetheless - the exposure is exogenous cytokine administration rather than the endogenous inflammation the model posits, the design is cohort rather than randomised for this question, and the remaining human evidence is case-control biomarker work to which universal cap 2 applies." }, { "rank_in_tournament": 2, "model_id": "M1", "is_nominal": true, "name": "Serotonin deficiency hypothesis", "core_claim": "Deficient serotonin neurotransmission causes MDD and SSRIs relieve it by correcting that deficiency.", "explains_what_nominal_does_not": null, "strongest_supporting_evidence": [ "Blinded within-subject depletion reverses antidepressant-induced remission and lowers mood in previously depressed people while doing nothing in never-depressed volunteers (C3, C4, C5)", "Reduced serotonin release capacity on a challenge PET paradigm in antidepressant-free patients (C6)", "SSRI superiority over placebo across a very large trial base (C9)" ], "strongest_contradictory_evidence": [ "No consistent evidence of lowered serotonin concentration or activity in depression (C1)", "Null candidate-gene and gene-by-stress findings in the largest samples (C7, C8)", "Depletion has no mood effect in never-depressed volunteers (C2, C3)", "Efficacy is equally consistent with non-serotonergic mediators that have prospective predictive support (C14, C15)" ], "hsef_level_for_this_model": "Γ", "rationale": "Ranks second, up from third in the input grading, because the input did not count the depletion-reversal literature at all. That literature is a blinded human mediator manipulation with a symptom endpoint and a positive result, which no other model in this tournament has. It does not rescue the nominal claim: it supports serotonin-dependence of a drug-induced state in previously depressed people, not a pre-existing deficit causing the disorder, and the deficiency premise remains unsupported. The tournament does not change the nominal's HSEF level." }, { "rank_in_tournament": 3, "model_id": "M2", "is_nominal": false, "name": "Neuroplasticity / BDNF hypothesis", "core_claim": "MDD reflects impaired synaptic plasticity and reduced BDNF signalling; antidepressants act by restoring plasticity rather than by correcting a monoamine deficit.", "explains_what_nominal_does_not": "Explains the weeks-long delay between the acute pharmacological action of antidepressants and clinical improvement, and the rapid action of ketamine.", "strongest_supporting_evidence": [ "In rodents, the behavioural actions of typical antidepressants are blocked by BDNF deletion and BDNF infusion into prefrontal cortex or hippocampus is sufficient to produce antidepressant-like effects (C14)", "Ketamine's synaptic and behavioural actions are blocked in BDNF null and BDNF Met knock-in mice (C14)" ], "strongest_contradictory_evidence": [ "Rodent BDNF gene deletion does not by itself produce depressive behaviour (C14)", "No human causal perturbation of BDNF signalling with a clinical endpoint exists", "Human evidence is post-mortem and imaging correlation" ], "hsef_level_for_this_model": "Γ", "rationale": "Strong rodent causal evidence and a coherent account of the onset delay, but every causal element is in animals with behavioural-despair readouts, which the rubric's rodent-proxy rule caps at Γ, and the human evidence is associational. Ranks below the nominal on causal evidence in humans, above it on mechanistic coherence. Demoted from rank 1 in the input grading, which credited it with 'the ketamine natural experiment' - ketamine's rapid effect is a drug effect in humans, not a perturbation of BDNF, and the BDNF dependence is demonstrated only in mice (C14)." }, { "rank_in_tournament": 4, "model_id": "M5", "is_nominal": false, "name": "Psychosocial stress model", "core_claim": "MDD is primarily initiated and maintained by adverse psychosocial stressors acting on a vulnerable substrate, with biological changes downstream.", "explains_what_nominal_does_not": "Explains why episodes commonly follow identifiable life events and why psychological treatment achieves comparable remission rates in milder depression.", "strongest_supporting_evidence": [ "Life-events epidemiology, which is consistent and large", "Randomised psychotherapy trials showing symptomatic benefit" ], "strongest_contradictory_evidence": [ "The epidemiological leg is associational and universal cap 2 binds it", "Psychotherapy trials test a treatment, not the causal model, and cannot be blinded in the sense this rubric requires" ], "hsef_level_for_this_model": "Γ", "rationale": "Scored as a preliminary expectation rather than from a dedicated ledger. The exposure-outcome association is among the most robust in psychiatry but is associational; the interventional leg tests treatment rather than causation. Γ is the ceiling until a perturbation of the stress pathway itself, rather than of its symptoms, is run." }, { "rank_in_tournament": 5, "model_id": "M4", "is_nominal": false, "name": "Default mode network / neural circuit hypothesis", "core_claim": "MDD reflects aberrant connectivity in the default mode network and frontal-limbic circuits, and treatment works by normalising it.", "explains_what_nominal_does_not": "Offers an account of rumination and of imaging differences not captured by monoamine measures.", "strongest_supporting_evidence": [ "Case-control functional-imaging differences and their normalisation after treatment" ], "strongest_contradictory_evidence": [ "The evidence base is observational imaging throughout", "Connectivity normalisation after treatment cannot distinguish cause from consequence of symptom change" ], "hsef_level_for_this_model": "Β", "rationale": "Scored as a preliminary expectation rather than from a dedicated ledger. Case-control imaging differences are exactly what the rubric's Β cap names, and no circuit perturbation with a diagnostic endpoint at clinical scale is on the record here." } ], "tournament_summary": "On the shared evidence the neuroinflammation model has the strongest human causal line bearing on the initiation of depression, and the nominal has the strongest human causal line bearing on maintenance of a treated state; the nominal ranks second of five, up from third in the input grading because that grading omitted the depletion-reversal literature entirely. All five models sit at Γ except the circuit model at Β, which is itself the finding: no model in this field has an uncontested human causal demonstration. The tournament does not change the nominal's HSEF level.", "study_separating_rank1_from_rank2": "The interferon-alpha incidence meta-analysis (C21): an exposure given to people without depression is followed by incident episodes, which is an initiation-relevant human causal line that the depletion literature cannot supply, because depletion does not induce depression in people who have never been depressed (C2, C3).", "nominal_wins_only_by_funding_artifact": false, "level_unchanged_by_tournament": true }, "evidence_inventory": [ { "citation": "Moncrieff J et al. 2023, Mol Psychiatry (umbrella review)", "source_pointer": "PMID 35854107 / DOI 10.1038/s41380-022-01661-0", "relates_to_subclaims": [ "SC1", "SC4" ], "favors_models": [ "M2", "M3", "M4", "M5" ], "evidence_class": "Moderate", "system": "human observational", "decisive_perturbation": false, "endogenous": false, "direction": "contradicts", "what_it_shows": "Across six areas of serotonin research the review finds no convincing evidence that depression is associated with, or caused by, lowered serotonin concentration or activity, and rates the depletion evidence for a family-history subgroup as very low certainty.", "what_it_does_not_show": "It does not synthesise its included meta-analyses quantitatively, does not examine the depletion literature in remitted patients as a causal test, and does not address whether serotonin availability is required to maintain a treated state.", "confounders_present": [ "Heterogeneous study units combined", "Certainty criteria devised for this review rather than a validated instrument", "Confounding by prior antidepressant use, acknowledged by the authors" ], "verification": "verified", "verification_note": "Full text read (PMC10618090) on 2026-09-27; conclusion and depletion sections quoted in the claim register.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "source_tier": "B" }, { "citation": "Jauhar S et al. 2023, Mol Psychiatry (comment)", "source_pointer": "PMID 37322065 / DOI 10.1038/s41380-023-02095-y", "relates_to_subclaims": [ "SC1", "SC4" ], "favors_models": [ "M1" ], "evidence_class": "Moderate", "system": "human observational", "decisive_perturbation": false, "endogenous": false, "direction": "supports", "what_it_shows": "A 35-author critique that the umbrella review's conclusion is overstated, reporting a large pooled depletion effect in the drug-free remitted stratum that the review did not present, and arguing that plasma-tryptophan and imaging findings indicate serotonergic involvement in vulnerable and depressed people.", "what_it_does_not_show": "It is a commentary, not new data; it does not defend the claim that a serotonin deficiency causes depression, and explicitly argues only that the system is implicated.", "confounders_present": [ "Author group overlaps substantially with the field's serotonergic research and industry-linked programmes", "No systematic re-analysis accompanies the critique" ], "verification": "verified", "verification_note": "Full text read (PMC10618084) on 2026-09-27.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "source_tier": "B" }, { "citation": "Moncrieff J et al. 2023, Mol Psychiatry (reply)", "source_pointer": "PMID 37322064 / DOI 10.1038/s41380-023-02094-z", "relates_to_subclaims": [ "SC1" ], "favors_models": [], "evidence_class": "Weak", "system": "human observational", "decisive_perturbation": false, "endogenous": false, "direction": "contradicts", "what_it_shows": "The umbrella review's authors maintain their conclusion in reply to the critique.", "what_it_does_not_show": "It adds no data and does not resolve the disagreement about the depletion subgroup analysis.", "confounders_present": [ "Correspondence; no independent adjudication" ], "verification": "verified", "verification_note": "Accessible portion of the correspondence read at the publisher page on 2026-09-27; recorded as full_text_partial.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "source_tier": "B" }, { "citation": "Ruhe HG et al. 2007, Mol Psychiatry (meta-analysis of monoamine depletion studies)", "source_pointer": "PMID 17389902 / DOI 10.1038/sj.mp.4001949", "relates_to_subclaims": [ "SC1", "SC4" ], "favors_models": [ "M1" ], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": true, "endogenous": true, "direction": "supports", "what_it_shows": "Stratified meta-analysis of depletion studies: no mood decrease in healthy controls, slight decrease with a family history of MDD, moderate decrease in drug-free remitted MDD, and relapse in remitted patients on serotonergic antidepressants.", "what_it_does_not_show": "Its own authors conclude that depletion studies fail to demonstrate a causal relation and instead clarify a vulnerability trait; it does not show that depressed people have low serotonin, and it does not test drug-naive currently depressed patients.", "confounders_present": [ "Protocol heterogeneity across component studies", "Overlapping research groups in the drug-free remitted stratum", "Depletion is not a serotonin-specific manipulation" ], "verification": "verified", "verification_note": "Abstract and PubMed record read on 2026-09-27. Note: the input grading cited PMID 17389903, which is a different paper in the same journal and volume.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "source_tier": "A" }, { "citation": "Delgado PL et al. 1990, Arch Gen Psychiatry", "source_pointer": "PMID 2184795 / DOI 10.1001/archpsyc.1990.01810170011002", "relates_to_subclaims": [ "SC3", "SC4" ], "favors_models": [ "M1" ], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": true, "endogenous": true, "direction": "supports", "what_it_shows": "Double-blind, placebo-controlled crossover depletion in 21 patients in antidepressant-induced remission: 14 relapsed during depletion and returned to remission on resuming normal intake, with no behavioural effect of the control drink.", "what_it_does_not_show": "It does not show that serotonin deficiency caused the original episode, and it cannot distinguish restoration of a prior deficit from dependence on a drug-elevated state. It had no healthy-control and no drug-naive arm.", "confounders_present": [ "Small sample", "Remitted, medicated state is not the depressed state", "Manipulation is not serotonin-specific" ], "verification": "verified", "verification_note": "Abstract and PubMed record read on 2026-09-27. Note: the input grading cited PMID 2268388, which is an unrelated cytometry paper, and attributed to this study a healthy-control and drug-naive comparison it does not contain.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "source_tier": "A" }, { "citation": "Erritzoe D et al. 2023, Biol Psychiatry", "source_pointer": "PMID 36635177 / DOI 10.1016/j.biopsych.2022.10.012", "relates_to_subclaims": [ "SC1" ], "favors_models": [ "M1" ], "evidence_class": "Weak", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "supports", "what_it_shows": "An amphetamine-challenge PET paradigm shows reduced serotonin release capacity in antidepressant-free patients in a depressive episode relative to controls.", "what_it_does_not_show": "The endpoint is receptor binding, not symptom trajectory, so it cannot show that the reduced release capacity contributes causally to the disorder; groups differ in age and the sample is small and unreplicated.", "confounders_present": [ "Small unreplicated sample", "Age imbalance between groups", "Biomarker endpoint with no functional outcome" ], "verification": "verified", "verification_note": "Abstract and PubMed record read on 2026-09-27.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "source_tier": "A" }, { "citation": "Culverhouse RC et al. 2018, Mol Psychiatry", "source_pointer": "PMID 28373689 / DOI 10.1038/mp.2017.44", "relates_to_subclaims": [ "SC1" ], "favors_models": [ "M5" ], "evidence_class": "Strong", "system": "human observational", "decisive_perturbation": false, "endogenous": false, "direction": "contradicts", "what_it_shows": "A uniform re-analysis of 31 datasets finds no statistically significant interaction between stress and 5-HTTLPR genotype under any outcome or stressor definition.", "what_it_does_not_show": "It does not exclude serotonergic involvement by other mechanisms, and a null genetic instrument is not evidence that the neurotransmitter is irrelevant.", "confounders_present": [ "European-ancestry samples only", "Heterogeneous stressor measures across cohorts" ], "verification": "verified", "verification_note": "Abstract and PubMed record read on 2026-09-27.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "source_tier": "A" }, { "citation": "Border R et al. 2019, Am J Psychiatry", "source_pointer": "PMID 30845820 / DOI 10.1176/appi.ajp.2018.18070881", "relates_to_subclaims": [ "SC1" ], "favors_models": [ "M5" ], "evidence_class": "Strong", "system": "human observational", "decisive_perturbation": false, "endogenous": false, "direction": "contradicts", "what_it_shows": "Across very large samples, 18 historical depression candidate genes show no main effects and no gene-by-environment effects, and are no more associated with depression than non-candidate genes.", "what_it_does_not_show": "It bears on the genetic instrument for the serotonin system, not on the neurotransmitter's role in symptom expression.", "confounders_present": [ "Common-variant analysis only", "Phenotype definitions vary across contributing samples" ], "verification": "verified", "verification_note": "Abstract and PubMed record read on 2026-09-27.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "source_tier": "A" }, { "citation": "Cipriani A et al. 2018, Lancet (network meta-analysis)", "source_pointer": "PMID 29477251 / DOI 10.1016/S0140-6736(17)32802-7", "relates_to_subclaims": [ "SC2" ], "favors_models": [ "M1", "M2", "M3" ], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": true, "endogenous": false, "direction": "supports", "what_it_shows": "All 21 antidepressants studied were more efficacious than placebo across 522 double-blind trials and 116,477 participants.", "what_it_does_not_show": "It does not establish mechanism, does not include any active-placebo comparison, and reports certainty of evidence as moderate to very low with most trials at moderate risk of bias.", "confounders_present": [ "Inert-placebo comparators throughout", "Industry sponsorship of most component trials", "Functional unblinding not measured in any component trial" ], "verification": "verified", "verification_note": "Abstract and PubMed record read on 2026-09-27.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "source_tier": "A" }, { "citation": "Kirsch I et al. 2008, PLoS Med (FDA-submission meta-analysis)", "source_pointer": "PMID 18303940 / DOI 10.1371/journal.pmed.0050045", "relates_to_subclaims": [ "SC2" ], "favors_models": [ "M1" ], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": false, "endogenous": false, "direction": "null", "what_it_shows": "In the complete FDA registration dataset for four new-generation antidepressants, the drug-placebo difference was 1.80 HRSD points and reached the NICE clinical-significance criterion only where mean baseline severity exceeded about 28, driven by declining placebo response.", "what_it_does_not_show": "It does not test the serotonin mechanism and does not show the drug effect is absent; the dataset contains almost no trials in the moderate-severity range. It re-analyses a subset of the same registration-trial base synthesised elsewhere here, so it is not counted as a separate decisive perturbation.", "confounders_present": [ "Imputed standard deviations for part of the dataset", "Group-level rather than patient-level data", "Sum-score outcome, contested as an efficacy measure" ], "verification": "verified", "verification_note": "Full text read (PMC2253608) on 2026-09-27; Results section figures recorded in the claim register.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "source_tier": "A" }, { "citation": "Jakobsen JC et al. 2017, BMC Psychiatry", "source_pointer": "PMID 28178949 / DOI 10.1186/s12888-016-1173-2", "relates_to_subclaims": [ "SC2" ], "favors_models": [], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": true, "endogenous": false, "direction": "null", "what_it_shows": "Across the 49 outcome-reporting trials of the 131 placebo-controlled SSRI trials in 27,422 participants included, the pooled effect was -1.94 HDRS points, below the reviewers' pre-defined threshold for clinical significance; none of the trials used an active placebo or no-intervention control and all were at high risk of bias.", "what_it_does_not_show": "It does not report blinding-integrity data and does not quantify how much of the effect unblinding could explain; it does not show SSRIs are ineffective.", "confounders_present": [ "All component trials at high risk of bias", "No active-placebo comparator anywhere in the set", "Clinical-significance threshold is the reviewers' own" ], "verification": "verified", "verification_note": "Abstract and PubMed record read on 2026-09-27. The input grading cited this work under a different journal, volume, pages, DOI and PMID; see the identifier audit.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "source_tier": "A" }, { "citation": "Moncrieff J, Wessely S, Hardy R. 2004, Cochrane Database Syst Rev", "source_pointer": "PMID 14974002 / DOI 10.1002/14651858.CD003012.pub2", "relates_to_subclaims": [ "SC2" ], "favors_models": [], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": true, "endogenous": false, "direction": "null", "what_it_shows": "Nine trials comparing antidepressants with active placebos in 751 participants give a pooled mood effect of 0.39 SD, falling to 0.17 (0.00-0.34) when one strongly positive trial is omitted; the authors conclude unblinding may inflate efficacy estimates from inert-placebo trials.", "what_it_does_not_show": "The included trials are predominantly tricyclic-versus-atropine comparisons, are old, are not pre-registered, and did not measure blinding integrity, so they do not satisfy the rubric's Δ comparator requirement for SSRIs.", "confounders_present": [ "High heterogeneity driven by one trial", "Tricyclic-dominated, so generalisation to SSRIs is an inference", "Blinding integrity not measured" ], "verification": "verified", "verification_note": "Abstract and PubMed record read on 2026-09-27.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "source_tier": "A" }, { "citation": "Hieronymus F et al. 2019, Lancet Psychiatry", "source_pointer": "PMID 31303567 / DOI 10.1016/S2215-0366(19)30216-0", "relates_to_subclaims": [ "SC2" ], "favors_models": [ "M1" ], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": false, "endogenous": false, "direction": "supports", "what_it_shows": "In a patient-level, item-based analysis of 8,262 participants from 28 SSRI trials, the reduction in depressed mood did not differ between non-severe and severe depression; the apparent severity dependence is an artefact of the 17-item sum score.", "what_it_does_not_show": "It is a post-hoc re-analysis of industry-sponsored trials, does not address mechanism, and does not remove the unblinding problem.", "confounders_present": [ "Post-hoc outcome definition", "Industry-sponsored source trials", "Author group holds a declared position in this dispute" ], "verification": "verified", "verification_note": "Abstract and PubMed record read on 2026-09-27.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "source_tier": "A" }, { "citation": "Harmer CJ, Duman RS, Cowen PJ. 2017, Lancet Psychiatry (review)", "source_pointer": "PMID 28153641 / DOI 10.1016/S2215-0366(17)30015-9", "relates_to_subclaims": [ "SC2", "SC3" ], "favors_models": [ "M2" ], "evidence_class": "Moderate", "system": "human observational", "decisive_perturbation": false, "endogenous": false, "direction": "null", "what_it_shows": "Reviews two contemporary accounts of antidepressant action - neuroplasticity and early change in negative affective bias - and reports that early drug-induced change in emotional processing predicts later clinical response and behaves as a specific treatment effect rather than a general expectancy mediator.", "what_it_does_not_show": "It does not report that the serotonin mediator has never been manipulated, and it states that all licensed antidepressants are believed to act at least initially by increasing serotonin or norepinephrine availability; it supplies no human causal perturbation of either rival mediator.", "confounders_present": [ "Review-level evidence", "The proposed cognitive mediator is itself untested by manipulation", "Rodent evidence for the plasticity account uses behavioural-despair readouts" ], "verification": "verified", "verification_note": "Full text read (PMC5410405) on 2026-09-27. The input grading attributed to this review an assertion it does not make; see the claim audit.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "source_tier": "B" }, { "citation": "Lacasse JR, Leo J. 2005, PLoS Med", "source_pointer": "PMID 16268734 / DOI 10.1371/journal.pmed.0020392", "relates_to_subclaims": [ "SC3" ], "favors_models": [], "evidence_class": "Weak", "system": "human observational", "decisive_perturbation": false, "endogenous": false, "direction": "contradicts", "what_it_shows": "Direct-to-consumer advertising claims that SSRIs correct a serotonin imbalance are not supported by the peer-reviewed literature.", "what_it_does_not_show": "It is a content analysis of advertising and tests neither efficacy nor mechanism.", "confounders_present": [ "Advertising is not the field's scientific claim", "Dated relative to the current evidence base" ], "verification": "verified", "verification_note": "Abstract and PubMed record read on 2026-09-27.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "source_tier": "B" }, { "citation": "Schroder HS et al. 2025, Front Psychol", "source_pointer": "PMID 39845538 / DOI 10.3389/fpsyg.2024.1469913", "relates_to_subclaims": [ "SC3" ], "favors_models": [], "evidence_class": "Weak", "system": "human observational", "decisive_perturbation": false, "endogenous": false, "direction": "contradicts", "what_it_shows": "In a survey of 1,219 students, hearing the chemical-imbalance explanation from a healthcare provider was the only source that uniquely predicted endorsing it.", "what_it_does_not_show": "It measures belief transmission, not the truth of the claim, and the sample is a single student population.", "confounders_present": [ "Convenience sample", "Self-reported recall of source", "Cross-sectional design" ], "verification": "verified", "verification_note": "Abstract and PubMed record read on 2026-09-27.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "source_tier": "A" }, { "citation": "Udina M et al. 2012, J Clin Psychiatry", "source_pointer": "PMID 22967776 / DOI 10.4088/JCP.12r07694", "relates_to_subclaims": [], "favors_models": [ "M3" ], "evidence_class": "Moderate", "system": "human observational", "decisive_perturbation": false, "endogenous": false, "direction": "supports", "what_it_shows": "Meta-analysis of 26 prospective studies: about a quarter of patients free of depression at baseline develop a major depressive episode during interferon-alpha therapy.", "what_it_does_not_show": "Exogenous cytokine administration is not the endogenous inflammatory state the neuroinflammation model claims, and the design is cohort rather than randomised for this question.", "confounders_present": [ "Non-randomised exposure", "Hepatitis C population is not representative", "Ribavirin co-administration" ], "verification": "verified", "verification_note": "Abstract and PubMed record read on 2026-09-27. Used only in the competing-model tournament.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] }, "source_tier": "A" } ], "verification_summary": { "load_bearing_claims_checked": 21, "verified": 21, "unverified": 0, "contradicted": 0, "note": "All 21 registered claims were checked against PubMed records on 2026-09-27, with full text read for sources 1, 2, 10 and 14 and the accessible portion of source 3. In addition, all eight ledger rows and all eight claims of the input grading were re-checked; four of its eight PMIDs resolved to unrelated papers and four of its eight claims were materially inaccurate. Those findings are recorded in factual_issues_found and in redteam/identifier-audit.md and redteam/claim-audit.md." }, "factual_issues_found": [ { "quoted_text": "Jakobsen JC, Katakam KK, Schou A, Hellmuth SG, Stallknecht SE, Leth-Moller K, et al. Selective serotonin reuptake inhibitors versus placebo in patients with major depressive disorder. A systematic review with meta-analysis and Trial Sequential Analysis. BMJ Evid Based Med. 2020;25(1):14-21. PMID 31953286. DOI 10.1136/bmjebm-2019-111238.", "problem": "A composite of three different records. The title and authors belong to a 2017 BMC Psychiatry systematic review; the DOI belongs to a different paper by an overlapping author group (BMJ Evid Based Med 2019;25(4):130); the journal, volume and pages match neither; and the PMID resolves to a veterinary article about mandibular malformation in calves.", "source_says": "The intended source is Jakobsen JC et al. BMC Psychiatry. 2017;17(1):58 (PMID 28178949, doi:10.1186/s12888-016-1173-2), which carries an erratum at BMC Psychiatry 2017;17(1):162.", "source_pointer": "PMID 28178949", "affects_score": true, "action": "scored-on-corrected-understanding" }, { "quoted_text": "All major SSRI RCTs used inert placebo and did not include blinding-integrity assessment, making functional unblinding an uncontrolled source of bias.", "problem": "The first half is supported by the corrected source; the second half - that the trials did not include blinding-integrity assessment - is asserted by neither the cited record nor the intended one, and this review could not verify it against any source. It was load-bearing: it was the stated trigger for the SC2 cap.", "source_says": "The intended source states that none of the 131 included trials used an active placebo or no intervention as a control and that all trials had high risk of bias. It makes no statement about blinding-integrity assessment.", "source_pointer": "PMID 28178949", "affects_score": true, "action": "scored-on-corrected-understanding" }, { "quoted_text": "Tryptophan depletion causes relapse in SSRI-remitted MDD patients but not in healthy controls or drug-naive patients, showing serotonin availability is required to maintain SSRI-induced remission.", "problem": "Attributed in the input grading to Delgado 1990 alone. That study enrolled patients in antidepressant-induced remission with sham depletion as the within-subject comparator; it had no healthy-control arm and no drug-naive arm, and its patients were on the antidepressants of 1990 rather than specifically on SSRIs. The healthy-control contrast comes from a different source.", "source_says": "Delgado 1990 reports 14 of 21 patients in antidepressant-induced remission relapsing during depletion, with no significant behavioural effect of control testing. The healthy-volunteer null is reported by the depletion meta-analysis (PMID 17389902).", "source_pointer": "PMID 2184795", "affects_score": true, "action": "scored-on-corrected-understanding" }, { "quoted_text": "No trial has independently manipulated serotonin correction as the independent variable to show it mediates SSRI antidepressant response; SSRIs may act via cognitive-neuropsychological mechanisms rather than by correcting serotonin deficiency.", "problem": "The first clause is attributed to a review that does not make it, and it is false as a statement about the literature: acute tryptophan depletion is a manipulation of serotonin availability carried out in humans with the antidepressant left in place and symptom trajectory as the outcome. It was load-bearing: it was the stated trigger for the SC3 mediation-by-correlation cap.", "source_says": "The cited review argues that acute monoamine potentiation does not explain the delayed clinical onset and proposes neuroplasticity and affective-bias accounts, while stating that all licensed antidepressants are believed to act at least initially by increasing serotonin or norepinephrine availability.", "source_pointer": "PMID 28153641", "affects_score": true, "action": "scored-on-corrected-understanding" }, { "quoted_text": "Functional unblinding: all reviewed SSRI RCTs used inert placebo without blinding-integrity assessment; apparent drug superiority may partly reflect expectancy effects in participants who are not truly blinded.", "problem": "Presented in the input grading as a verbatim quotation of the rubric's functional-unblinding cap. No such text appears in 07-psychiatry-neuromodulation.md. The same applies to the quoted 'mediation inferred from correlation' cap and to all three of the quoted 'field-valid causal perturbation' definitions in the boundary check.", "source_says": "The rubric reads: 'Functional-unblinding rule. Inert-placebo trial of an intervention with unmistakable acute subjective effects - psychedelics, ketamine, entactogens, suprathreshold stimulation, ECT - with no blinding-integrity check reported. Such a trial did not control what it claims to control.'", "source_pointer": "pkt/schema/references/evidence-rubrics/07-psychiatry-neuromodulation.md", "affects_score": true, "action": "scored-on-corrected-understanding" }, { "quoted_text": "Two index adjudication notes were applied: (1) the functional-unblinding cap applies to all inert-placebo SSRI RCTs ... (2) tryptophan depletion failure in healthy subjects is a negative perturbation result and does not cross Δ.", "problem": "Presented as notes from hypothesis-index.md. The index contains no entry for this hypothesis and neither note appears in it. The second proposition is sound on its own terms but is a framework boundary-check clause, not an index note.", "source_says": "hypothesis-index.md has no serotonin or monoamine entry; its only psychiatry entry is the psilocybin dual-phase hypothesis.", "source_pointer": "pkt/schema/references/hypothesis-index.md", "affects_score": false, "action": "logged" } ], "cap_rules_applied": [ { "subclaim_id": "SC1", "cap": "Β", "cap_source": "universal", "triggered": false, "trigger_text_quoted": "Pure association evidence - however large, however replicated - cannot exceed Β. GWAS, epidemiology, postmortem colocalization, transcriptomic signatures, and diversity metrics are associational unless paired with causal manipulation.", "specific_trigger": "The cap fires on the associational leg of SC1 - 5-HIAA and plasma serotonin, receptor and transporter imaging, candidate-gene and gene-by-stress studies (C1, C6, C7, C8) - and that leg therefore cannot carry SC1 above Β on its own. It is recorded as not triggered at subclaim level because SC1's evidence base is not association-only: it also contains a human depletion-challenge programme with symptom-trajectory outcomes (C2, C3) and an unblinded human pharmacological challenge (C6). A cap binds the inference from one evidence class, not from a base assembled from several (pitfall 21). This is the point on which this edition departs from the input grading.", "resulting_ceiling": "Β" }, { "subclaim_id": "SC1", "cap": "Γ", "cap_source": "rubric", "triggered": true, "trigger_text_quoted": "Mechanistic plausibility with in vitro, rodent, or unblinded human support caps at Γ.", "specific_trigger": "The sourced human support for SC1 is partial and does not reach Δ: an open-label amphetamine-challenge PET comparison with a positive but biomarker-only result (C6); the pharmacology of licensed antidepressants, all believed to act at least initially by increasing serotonin or norepinephrine availability (C14); and a blinded depletion programme whose positive results lie outside SC1's population and whose result in never-depressed volunteers is null (C2, C3). The 'unblinded human support' limb of the cap describes this base. No rodent evidence is relied on. This is the binding ceiling for SC1.", "resulting_ceiling": "Γ" }, { "subclaim_id": "SC1", "cap": "Γ", "cap_source": "universal", "triggered": true, "trigger_text_quoted": "Biomarker change without functional/phenotypic change caps at Γ. This applies even when the biomarker change is mechanistically informative.", "specific_trigger": "The challenge-PET finding of reduced serotonin release capacity (C6) is a binding measure with no accompanying symptom outcome; the rubric's acute-pharmacodynamic rule - 'Acute molecular, occupancy, or imaging change with no link to symptom trajectory' - says the same thing.", "resulting_ceiling": "Γ" }, { "subclaim_id": "SC2", "cap": "Γ", "cap_source": "rubric", "triggered": true, "trigger_text_quoted": "Mechanistic plausibility with in vitro, rodent, or unblinded human support caps at Γ.", "specific_trigger": "The SSRI trial base is large and positive but consists entirely of inert-placebo comparisons whose blinding was never verified (C9, C11, C12); the rubric classes an inert-placebo RCT that does report blinding-integrity data as Moderate evidence, and these trials do not reach even that bar. Δ requires a comparator this literature does not contain.", "resulting_ceiling": "Γ" }, { "subclaim_id": "SC2", "cap": "Γ", "cap_source": "rubric", "triggered": false, "trigger_text_quoted": "Functional-unblinding rule. Inert-placebo trial of an intervention with unmistakable acute subjective effects - psychedelics, ketamine, entactogens, suprathreshold stimulation, ECT - with no blinding-integrity check reported. Such a trial did not control what it claims to control.", "specific_trigger": "Recorded as not triggered as written. The rule names interventions with unmistakable acute subjective effects and enumerates them; SSRIs are not among them, and their side-effect profile, while noticeable, is not the acute psychoactive experience the rule targets. The concern the rule expresses is nonetheless live here and is addressed through the Δ threshold and through the active-placebo evidence (C12), which is the empirical form of the same question. The input grading fired this rule against a quotation that does not appear in the rubric; whether the enumeration is meant to be exhaustive is flagged for the rubric's maintainer.", "resulting_ceiling": "Γ" }, { "subclaim_id": "SC3", "cap": "Γ", "cap_source": "rubric", "triggered": true, "trigger_text_quoted": "Mechanistic plausibility with in vitro, rodent, or unblinded human support caps at Γ.", "specific_trigger": "Nothing on the record distinguishes correcting a pre-existing deficit from elevating a system that was not deficient. The deficit premise fails at SC1, and the one human mediator manipulation available (C3, C5) is silent on the distinction.", "resulting_ceiling": "Γ" }, { "subclaim_id": "SC3", "cap": "Γ", "cap_source": "rubric", "triggered": false, "trigger_text_quoted": "Mediation-by-correlation rule. Candidate mediator correlated with outcome, never manipulated.", "specific_trigger": "Recorded as not triggered. The mediator has been manipulated in humans, repeatedly, with the drug left in place and symptom trajectory as the outcome (C3, C5). The input grading fired this rule on the strength of an assertion that no such manipulation exists, which the record contradicts. SC3 is held at Γ for a different and better reason: the manipulation tests serotonin-dependence, not deficit correction.", "resulting_ceiling": "Γ" }, { "subclaim_id": "SC4", "cap": "Γ", "cap_source": "rubric", "triggered": false, "trigger_text_quoted": "Mechanistic plausibility with in vitro, rodent, or unblinded human support caps at Γ.", "specific_trigger": "Not triggered: SC4 does not rest on rodent or unblinded human support. Its anchor is a blinded, within-subject human mediator manipulation with a symptom-trajectory endpoint and a positive result (C3, C4, C5), which is one of the rubric's own field-valid causal perturbations.", "resulting_ceiling": "Δ" } ], "cap_precedence_resolutions": [ { "collision": "Universal cap 2 (pure association cannot exceed Β) versus rubric 07's Γ cap and Δ threshold, on SC1.", "subclaim_scope_cap_binds_on": "The inference from the associational evidence class - metabolite, receptor and transporter imaging, candidate-gene and gene-by-stress studies - to the disease-class claim that a serotonin deficiency causes MDD. No quantity of that evidence carries SC1 past Β.", "subclaim_scope_threshold_binds_on": "SC1 as a whole, whose base also includes a human depletion-challenge programme with symptom endpoints and an unblinded human pharmacological challenge. Within that base the rubric's Γ cap is the binding ceiling and the Δ threshold is the next rung tested.", "resolution": "A perturbation crosses a threshold within the system it was actually run in; a universal cap governs the inference from that system to the hypothesis's claimed scope. Applied here, cap 2 governs the associational leg and rubric 07's Γ cap governs the subclaim. Recording it the other way round - letting cap 2 set the subclaim ceiling because one leg is associational - is pitfall 21, and is what produced the input grading's Β.", "note": "Never resolve a collision silently. This resolution is the single reason the overall letter moved, and the contrary reading is set out in the steelman." }, { "collision": "Rubric 07's Δ threshold sentence requires 'a pre-registered primary outcome'; the depletion literature that satisfies its field-valid perturbation list predates trial registration.", "subclaim_scope_cap_binds_on": "SC4, where the qualifying evidence is a body of blinded crossover studies conducted between 1990 and the mid-2000s.", "subclaim_scope_threshold_binds_on": "SC4.", "resolution": "The pre-registration clause is read as attaching to the trial-design limb of the sentence rather than to the mediator-manipulation limb. The contrary reading would hold every depletion study below Δ on a publication-era technicality, which the framework's own upper-ladder section warns against: a framework that penalises a causal literature for its study-design era is measuring design rather than causal knowledge. The alternative reading is disclosed rather than suppressed, and would return Γ for SC4 without changing the overall letter.", "note": "Flagged for the rubric's maintainer as a textual ambiguity." } ], "boundary_check_BGD": [ { "subclaim_id": "SC1", "field_valid_perturbation_quote": "Depletion or challenge experiment in humans whose outcome is symptom trajectory, not a biomarker", "qualifying_evidence_present": "yes", "qualifying_evidence_citation": "The acute tryptophan depletion literature, meta-analysed in C3 and surveyed in C2.", "gamma_hard_rules_triggered": [ "'Acute-pharmacodynamic rule. Acute molecular, occupancy, or imaging change with no link to symptom trajectory.' - triggered by the challenge-PET release-capacity finding (C6).", "'Rodent-proxy rule. Forced-swim, tail-suspension, sucrose-preference, or head-twitch alone; head-twitch is pharmacodynamic, not therapeutic.' - not triggered; no rodent evidence is relied on for SC1 in this review.", "'Mediation-by-correlation rule. Candidate mediator correlated with outcome, never manipulated.' - not triggered; the mediator has been manipulated.", "'Open-label rule. Open-label, single-arm, retrospective, or naturalistic evidence alone. A positive open-label result never crosses Δ, however large.' - not triggered.", "'Unblinded-rater rule. Outcomes rated by clinicians who delivered the intervention or knew allocation.' - not triggered." ], "disease_phenotype_relevance": "yes", "perturbation_result_positive": "no", "perturbation_result_note": "Clause 5 decides SC1. The qualifying perturbation is negative in the population the subclaim needs: depletion produces no mood effect in most healthy volunteers, and the family-history signal is rated very low certainty and was not confirmed by subsequent studies (C2, C3). A negative field-valid perturbation does not cross Δ (pitfall 17). No depletion experiment in drug-naive, currently depressed patients is on the record.", "ceiling_from_boundary_check": "Γ" }, { "subclaim_id": "SC2", "field_valid_perturbation_quote": "Active comparator matched for acute subjective effect, blinding integrity measured and reported", "qualifying_evidence_present": "no", "qualifying_evidence_citation": "No SSRI trial with a comparator matched for acute subjective effect and measured blinding integrity exists; none of the 131 trials in C11 used an active placebo, and the nine active-placebo trials in C12 are tricyclic-dominated, unregistered and did not measure blinding integrity.", "gamma_hard_rules_triggered": [ "'Functional-unblinding rule. Inert-placebo trial of an intervention with unmistakable acute subjective effects - psychedelics, ketamine, entactogens, suprathreshold stimulation, ECT - with no blinding-integrity check reported.' - not triggered as written; SSRIs are not among the enumerated interventions. Recorded openly rather than extended by analogy.", "'Open-label rule ...' - not triggered; the trial base is randomised and double-blind by design.", "'Unblinded-rater rule ...' - not triggered; raters were nominally blinded, though blinding integrity was never measured." ], "disease_phenotype_relevance": "yes", "perturbation_result_positive": "yes", "perturbation_result_note": "The result is positive and large in volume (C9), which is why SC2 sits at the Γ ceiling rather than below it. Δ fails on the comparator, not on the result.", "ceiling_from_boundary_check": "Γ" }, { "subclaim_id": "SC3", "field_valid_perturbation_quote": "Mediator manipulation with the intervention intact: antagonist blockade of the acute experience with the drug still given, or dosing under general anaesthesia", "qualifying_evidence_present": "yes", "qualifying_evidence_citation": "Acute tryptophan depletion administered with the antidepressant still in place (C3, C5).", "gamma_hard_rules_triggered": [ "'Mediation-by-correlation rule. Candidate mediator correlated with outcome, never manipulated.' - not triggered; the mediator has been manipulated in humans.", "'Acute-pharmacodynamic rule ...' - not triggered for this subclaim; the depletion endpoint is symptom trajectory." ], "disease_phenotype_relevance": "yes", "perturbation_result_positive": "no", "perturbation_result_note": "Positive for a different proposition. The manipulation shows the drug response depends on serotonin availability; SC3 claims the drug works by correcting a pre-existing deficit. Nothing in the paradigm distinguishes restoration of a deficit from displacement of a system that was not deficient, and the deficit premise fails at SC1. For the proposition SC3 actually asserts, no qualifying perturbation has been run.", "ceiling_from_boundary_check": "Γ" }, { "subclaim_id": "SC4", "field_valid_perturbation_quote": "Depletion or challenge experiment in humans whose outcome is symptom trajectory, not a biomarker", "qualifying_evidence_present": "yes", "qualifying_evidence_citation": "C5 (blinded within-subject depletion reversing antidepressant-induced remission in 14 of 21 patients) and C3 and C4 (the meta-analysed drug-free remitted stratum).", "gamma_hard_rules_triggered": [ "'Mediation-by-correlation rule ...' - not triggered.", "'Acute-pharmacodynamic rule ...' - not triggered; the endpoint is symptom trajectory.", "'Rodent-proxy rule ...' - not triggered; the evidence is human.", "'Open-label rule ...' - not triggered; the studies are blinded and placebo-controlled within subject.", "'Unblinded-rater rule ...' - not triggered." ], "disease_phenotype_relevance": "yes", "perturbation_result_positive": "yes", "perturbation_result_note": "Positive, blinded, within-subject, human, with a symptom endpoint, and with an internal comparison group in which the effect is absent. This is the one place in the hypothesis where a field-valid perturbation returns a positive result.", "ceiling_from_boundary_check": "Δ or higher" } ], "thresholds_tested": [ { "subclaim_id": "SC1", "threshold": "Δ", "requirement_quoted": "Requires a controlled human interventional study with a credible active comparator, or a mediator manipulation in humans, with a pre-registered primary outcome.", "satisfied": "no", "supporting_evidence": [ "C2 and C3: depletion has no mood effect in most healthy volunteers; the family-history signal is very low certainty and unconfirmed." ], "what_would_cross_it": "A blinded depletion or challenge experiment in drug-naive people with a current depressive episode, or in never-depressed volunteers, producing a clinically meaningful worsening relative to sham, with a manipulation check showing the intervention changed serotonergic transmission specifically." }, { "subclaim_id": "SC2", "threshold": "Δ", "requirement_quoted": "Requires a controlled human interventional study with a credible active comparator, or a mediator manipulation in humans, with a pre-registered primary outcome.", "satisfied": "no", "supporting_evidence": [ "C9: SSRIs outperform inert placebo across 522 trials.", "C12: against active placebo the pooled effect is 0.39 SD, and 0.17 (0.00-0.34) on sensitivity analysis, in a tricyclic-dominated set." ], "what_would_cross_it": "A pre-registered SSRI trial against a comparator matched for acute subjective effect, with allocation-guess data collected from participants and raters and reported, showing the drug effect survives adjustment for guessed allocation." }, { "subclaim_id": "SC3", "threshold": "Δ", "requirement_quoted": "Requires a controlled human interventional study with a credible active comparator, or a mediator manipulation in humans, with a pre-registered primary outcome.", "satisfied": "no", "supporting_evidence": [], "what_would_cross_it": "An experiment that separates deficit correction from pharmacological displacement: response stratified by an independently measured baseline index of serotonergic function, or a design in which the serotonergic effect is delivered to people shown not to be deficient." }, { "subclaim_id": "SC4", "threshold": "Δ", "requirement_quoted": "Requires a controlled human interventional study with a credible active comparator, or a mediator manipulation in humans, with a pre-registered primary outcome.", "satisfied": "yes", "supporting_evidence": [ "C5: 14 of 21 remitted patients relapsed during blinded depletion and recovered on resumption, with no effect of control testing.", "C3 and C4: the meta-analysed drug-free remitted stratum shows a moderate to large mood decrease.", "C2 and C3: no effect in never-depressed volunteers, the internal negative comparison." ], "what_would_cross_it": "n/a - satisfied. The pre-registration clause is the one element not met by this literature; see cap_precedence_resolutions." }, { "subclaim_id": "SC4", "threshold": "Ε", "requirement_quoted": "Requires causal support restricted to a defined context - one diagnosis, one severity stratum, one treatment-resistant subgroup, or only with the accompanying psychotherapeutic scaffold.", "satisfied": "partial", "supporting_evidence": [ "The context is defined and determinable at enrollment: a documented history of MDD with current remission.", "The internal negative comparison in never-depressed volunteers marks where the effect stops (C2, C3)." ], "what_would_cross_it": "A cleanly mapped boundary: replication of the drug-free remitted result by a group independent of those that produced it, a serotonin-specific manipulation check separating depletion's serotonergic from its non-serotonergic effects, and resolution of the recent crossover studies in depressed patients that showed no convincing effect (C2). Until then the boundary is suggested rather than mapped, and Ε is not taken (pitfall 16 cuts both ways)." } ], "generalization_check": { "generalization_tested": "yes", "context_boundary_mapped": "no", "internal_negative_controls": [ "Depletion produces no mood decrease in healthy volunteers without a family history of depression (C2, C3) - the negative comparison that bounds the positive results.", "The family-history stratum shows only a slight decrease, rated very low certainty, and a later study found no difference between family-history and non-family-history volunteers (C2)." ], "note": "Generalization was tested and fails: the depletion effect does not extend to never-depressed people. Under pitfall 16 a failed generalization with a mapped boundary is Ε, not a reason to sit below it. The boundary here is suggested but not mapped to the standard that rule contemplates - the strata come from heterogeneous study sets rather than a single design with internal controls, several drug-free-remitted samples share research groups, and the manipulation's specificity for serotonin is contested. SC4 therefore rests at Δ with Ε named as the next rung and the conditions for it stated." }, "falsification_patterns_met": [], "pitfalls_flagged": [ { "subclaim_id": "SC1", "pitfall": "Pitfall 21 - A universal cap re-applied to a convergent evidence set", "where": "The input grading applied cap 2 to SC1 as a whole because its biomarker and genetic legs are associational, and returned Β. The subclaim's base also contains a human depletion-challenge programme; the cap binds the associational leg, not the subclaim." }, { "subclaim_id": "SC1", "pitfall": "Pitfall 1 - Mistaking presence for primacy", "where": "Serotonin-system differences in imaging and metabolite studies are read as evidence of causal deficiency; the same differences are equally consistent with consequence, with medication history, or with nothing." }, { "subclaim_id": "SC1", "pitfall": "Pitfall 17 - Negative field-valid perturbation read as a crossed threshold", "where": "Avoided here and correctly avoided in the input grading. The healthy-volunteer depletion null is of exactly the right design and does not cross Δ; it is recorded as blocking the threshold, not as supporting it." }, { "subclaim_id": "SC2", "pitfall": "Pitfall 10 - Mechanism conflation", "where": "The input grading's SC2 read 'SSRIs significantly and specifically relieve MDD'. The word 'specifically' imports the mechanism question into the efficacy subclaim and double-counts it against SC3; it has been removed and returned to SC3." }, { "subclaim_id": "SC3", "pitfall": "Pitfall 13 - Therapeutic effect misread as mechanistic proof", "where": "The hypothesis's historical warrant is the backward inference from SSRI efficacy to a serotonin deficit. Efficacy constrains mechanism only weakly, and the rival mediators reviewed in C14 and C15 are compatible with the same trial results." }, { "subclaim_id": "SC4", "pitfall": "Pitfall 11 - Intervention specificity assumed rather than demonstrated", "where": "Acute tryptophan depletion is treated as a serotonin manipulation. The umbrella review notes that the procedure also alters BDNF, amino-acid balance and cerebrovascular parameters, and that it is unclear whether it reliably lowers brain serotonin. This is the main reason SC4 is held at Δ with Moderate confidence rather than taken higher." }, { "subclaim_id": "SC4", "pitfall": "Pitfall 16 - Failed generalization mistaken for weak evidence", "where": "Considered and applied in both directions: the failure to generalise to never-depressed volunteers is not a reason to hold SC4 below Δ, but the boundary is not mapped cleanly enough to take Ε." }, { "subclaim_id": "SC1", "pitfall": "Pitfall 18 - Causal-evidence tallies that do not survive an audit", "where": "The input grading audited its own causal tally to zero creditable items. Recounting against the cap rules returns two: the depletion meta-analysis and the depletion-reversal experiment, both positive, endogenous, human and phenotype-relevant, both bearing on SC4 rather than on SC1." }, { "subclaim_id": "SC1", "pitfall": "Pitfall 19 - Unlinked claims", "where": "The input grading's tournament and upper-ladder sections name studies and results - a ketamine trial, BDNF knockout work, interferon-alpha depression, 5-HTTLPR instruments, SSRI dose-response - with no ledger row behind any of them. Those that survive here carry a source; those that could not be resolved were removed or restated generically." } ], "causal_tally_audit": { "tally_claimed_by_document": 0, "tally_after_audit": 2, "items_rejected": [ "Challenge-PET serotonin release capacity (C6): universal cap 4 and the rubric's acute-pharmacodynamic rule - a binding measure with no symptom endpoint is not a causal item for a disease claim.", "Cipriani network meta-analysis (C9): a decisive perturbation for SC2 but not a perturbation of the endogenous mechanism; it is drug administration against an inert comparator.", "Jakobsen systematic review (C11) and the active-placebo Cochrane review (C12): same reason; counted for SC2's threshold test, not as causal items for the serotonin claim.", "Candidate-gene and gene-by-stress studies (C7, C8): observational, and null.", "Interferon-alpha incidence meta-analysis (C21): a causal item for the neuroinflammation rival, not for this hypothesis, and non-randomised." ] }, "steelman": { "case_one_rung_higher": "The case for Δ overall. SC4 crosses Δ on the rubric's own field-valid perturbation list, and a reader could argue the aggregation is being used to bury it: the hypothesis's second clause predicts that removing serotonin should remove the benefit, that prediction was tested in humans under blind conditions, and it held (C3, C4, C5). Add the reduced serotonin release capacity in unmedicated patients (C6), the lower plasma tryptophan reported in the critique literature, and the fact that every licensed antidepressant acts at least initially on monoamine availability (C14), and the picture is of a system that is perturbed in depression and causally load-bearing for recovery. On that reading the weakest clause is not a failure of the mechanism but a failure of the deficiency framing, and the hypothesis restated as 'serotonergic transmission is causally involved in depressive states' would sit at Δ or Ε.", "case_one_rung_lower": "The case for Β, which is the input grading's answer. Every direct measurement of serotonin in depression is associational and the largest synthesis finds no consistent signal (C1); the genetic instruments are null in the largest samples ever assembled (C7, C8); the depletion literature's own meta-analysts say it fails to demonstrate a causal relation and instead marks a vulnerability trait (C3); and the manipulation may not even be serotonin-specific. On this reading the human challenge and pharmacological evidence that lifts SC1 to Γ supports serotonergic involvement in mood regulation in general, not the deficiency claim actually graded, and importing it is charity in scoring.", "which_rejected": "Both. Δ is rejected for the overall letter and Β is rejected for SC1; the level is Γ.", "blocking_cap_threshold_or_missing_experiment": "Δ is blocked by the aggregation rule operating on a genuinely conjunctive claim: SC4 is not the graded claim, it is a necessary condition of the graded claim's second clause, and SC1, SC2 and SC3 each independently fail the Δ threshold - SC1 on boundary-check clause 5 (the qualifying perturbation is null in never-depressed volunteers, C2, C3), SC2 on the absence of any comparator matched for acute subjective effect with measured blinding integrity (C11, C12), SC3 on the absence of any experiment distinguishing deficit correction from pharmacological displacement. Β is rejected because rubric 07's Γ cap, not universal cap 2, is the rule that binds a subclaim whose evidence base includes a human mediator manipulation; treating one associational leg as the ceiling for the whole is pitfall 21. The missing experiment that would settle the direction is a depletion or challenge study in drug-naive, currently depressed patients with a serotonin-specific manipulation check." }, "final_score": { "hsef_level": "Γ", "hsef_descriptor": "Mechanistically plausible, partial system support", "confidence": "Moderate", "confidence_rationale": "Evidence density is high for the efficacy clause and moderate for the serotonin clause, but reproducibility in the serotonin literature is demonstrably poor: the candidate-gene and gene-by-stress programme collapsed in the largest samples (C7, C8), the imaging findings are inconsistent across reviews and confounded by medication history (C1), the depletion literature is heterogeneous in protocol and partly concentrated in overlapping groups (C3, C4), and the single direct measure of release capacity is unreplicated with 17 patients (C6). That is the framework's description of Moderate, not High. The input grading's High rested on a base of eight abstract-only sources of which four carried identifiers pointing at unrelated papers.", "rests_on_non_peer_reviewed_work": false, "rationale": "Weakest-link over SC1=Γ, SC2=Γ, SC3=Γ, SC4=Δ gives Γ. The mechanism is plausible and has partial human support - an unblinded challenge study, the pharmacology of the drugs themselves, and one positive human mediator manipulation; what has not been shown is the endogenous, disease-relevant causal dependency the claim asserts - that a serotonin deficiency exists in depression and that correcting it is how treatment works." }, "role_of_mechanism": { "classification": "reinforcing / stabilizing factor", "derivation_step_matched": "5", "derivation": "Step 1 does not match: nothing shows serotonin change is produced by the depressive state rather than producing it. Step 2 does not match either, which is where this edition departs from the input grading: epiphenomenon requires no demonstrated causal dependency in either direction, and a dependency has been demonstrated in one direction - lowering serotonin availability reinstates symptoms in people with a history of depression and reverses antidepressant-induced remission under blind conditions (C3, C5). Step 3 fails on all three tests: removing serotonin does not prevent depression, engaging it does not initiate the disorder in never-depressed people (C2, C3), and nothing shows it is rate-limiting. Step 4 fails: serotonin is not shown to be required for the phenotype to arise. Step 5 therefore matches - the mechanism maintains and modulates a state initiated upstream.", "tournament_used_as_tiebreaker": false, "note": "Derived from direction of causation, not tournament rank. The nominal ranks second of five; that played no part in this derivation." }, "extended_scoring_MSD": { "momentum": { "value": "Associational only", "artifact": "The decisive designs are not being run. A ClinicalTrials.gov search on 2026-09-27 for tryptophan-depletion studies in depression returns only completed observational records registered in the early 2000s, and no registered SSRI trial against a comparator matched for acute subjective effect; where the active-placebo design does appear in current depression trials it is midazolam against ketamine, not a serotonergic comparator. The last systematic synthesis of the depletion literature remains the 2007 meta-analysis, a gap the umbrella review itself notes. New output since 2022 is dominated by re-analysis and the umbrella-review controversy (C1, C2, C19, C20).", "justification": "Causal output on this hypothesis has stalled while commentary has grown; the two experiments that would move any of the four subclaims are absent from the registries." }, "stability": { "value": "Stable", "trigger": "No pending result can be named that would move the letter. The named candidates do not qualify: replication of the reduced-release-capacity finding would strengthen an association that universal cap 4 already holds at Γ; a further umbrella review would re-synthesise the same primary literature; and the Moncrieff-Jauhar exchange has already been published in full without adding data. The framework's rule applies - if no trigger can be named, the answer is Stable by definition.", "justification": "This is a change from the input grading's Eroding, which named continued publication of umbrella reviews and rival-model findings. Those are not level-moving results, and the exchange they pointed to has already happened." }, "divergence": { "implied_level": "Ζ", "implied_level_basis": "Measured against how the claim is presented outside the specialist literature, which is where this hypothesis has its influence. The umbrella review records that surveys indicate most of the general public believes it is established that depression is caused by a chemical imbalance and that many general practitioners share that view (C17); direct-to-consumer advertising asserted serotonin correction outright (C16); and hearing the explanation from a healthcare provider is the source that uniquely predicts endorsing it (C18). A reader taking that framing at face value would infer multiple converging causal lines, which is Ζ.", "assessed_level": "Γ", "gap_in_rungs": 3, "value": "Severe overstatement", "justification": "Patient-facing framing implies Ζ; assessed Γ; Ζ is three rungs above Γ, so +3, severe overstatement. Stated explicitly, because the choice of reference framing decides the answer: measured instead against the current specialist literature the arithmetic is different and much smaller. Contemporary reviews do not defend the deficiency claim - one of the most-cited treats the monoamine account as inadequate to explain antidepressant action (C14), and even the 35-author defence of the field claims only that the serotonin system is 'implicated' (C20) - so specialist framing implies about Δ, giving +1, mild overstatement. The severe value therefore measures the gap between evidence and clinical or public communication, not a gap between evidence and what the field now argues in print. The headline value uses the public and patient-facing reference class; the specialist-literature reference class gives +1, mild. The corpus-wide choice of reference class is flagged for the owner to settle." }, "calibration_note": "M/S/D never modify HSEF level or confidence (Rule 10). Each carries its artifact. The three no longer sit at the corpus-modal triple: Stability moved to Stable because no level-moving trigger could be named." }, "change_record": { "applies": true, "prior_level": "Β", "prior_confidence": "High", "prior_source": "sources/A_v5.4_grading (reviewer recorded as 'HSEF Review Agent v5.0', schema 5.4, 2026-09-27); no validation report was shipped with it, and the coordinator's re-run of validator 2.4 returned 0 fail / 1 warn.", "derived_before_consulting_prior": false, "new_level": "Γ", "direction": "raised", "what_moved_it": "SC1 moved Β to Γ. Universal cap 2 had been applied to SC1 as a whole; it binds the associational leg - metabolites, receptor and transporter imaging, candidate genes - and not a subclaim whose base also contains a human depletion-challenge programme and an unblinded human pharmacological challenge (pitfall 21; framework, 'caps bind the inference from a single evidence class'). Rubric 07's Γ cap, 'Mechanistic plausibility with in vitro, rodent, or unblinded human support caps at Γ', is the binding ceiling, and boundary-check clause 5 blocks Δ because the qualifying depletion experiment is null in never-depressed volunteers. Under weakest-link the overall letter followed SC1 from Β to Γ. A fourth subclaim was added at Δ for the proposition the input omitted - that serotonin availability is required to maintain the recovered state - which does not move the aggregate but corrects a causal tally the input had audited to zero. SC2 and SC3 held at Γ with their governing rules replaced: both had been fixed by rubric caps quoted in words that do not appear in the rubric, and SC3's cap was contradicted by the record.", "divergence_from_other_reviewers": "This is a revision of a single input grading, and it differs from it on five substantive points, each recorded with its reason in redteam/pass-01-2026-09-27.md: the SC1 cap attribution (input Β, this edition Γ); the existence of a positive human mediator manipulation (input: none exists; this edition: the depletion-reversal literature); the identity of the caps governing SC2 and SC3 (input quoted rubric text that does not exist); the role of mechanism (input epiphenomenon, this edition reinforcing / stabilizing factor, because a causal dependency has been demonstrated in one direction); and Stability (input Eroding with no nameable level-moving trigger, this edition Stable). The input's case for Β is written out in full in the steelman and was rejected on the named cap-precedence rule, not on a difference of impression. The input's level was consulted before this pass began - the brief supplied it - so the anchoring safeguard of Rule 12 could not be met; this is disclosed rather than asserted away, and the mitigation used was to derive each subclaim from the rubric text and the retrieved records before comparing with the input's letters." }, "proposed_decisive_experiments": [ { "name": "Depletion challenge in drug-naive, currently depressed patients with a specificity control", "experiment": "Blinded, within-subject acute tryptophan depletion versus a balanced amino-acid control in adults with a current, first-episode depressive episode who have never taken a psychotropic drug, with a parallel arm receiving a depletion procedure matched for amino-acid load and cerebrovascular effect but not for tryptophan.", "readout": "Change in a clinician-rated depression score at 6 and 24 hours, with plasma tryptophan to large-neutral-amino-acid ratio as the manipulation check and a serotonergic neuroendocrine or imaging index to demonstrate the manipulation acted where it is claimed to.", "critical_control": "The matched non-tryptophan-depleting arm, which separates serotonergic depletion from the procedure's other effects - the specificity gap that currently caps SC4 at Δ.", "falsifying_result": "No difference between depletion and control in drug-naive depressed patients, with a confirmed manipulation check, would leave SC1 at Γ permanently and would place the depletion effect wholly in the previously-treated or previously-depressed state.", "supporting_result": "Clinically meaningful worsening under depletion but not under the matched control would cross Δ for SC1 and would be the first positive field-valid perturbation for the causation clause." }, { "name": "SSRI against a subjective-effect-matched comparator with measured blinding integrity", "experiment": "Pre-registered randomised trial of an SSRI against an active placebo chosen to reproduce its early side-effect profile, with allocation-guess and confidence ratings collected from participants and from raters at every visit.", "readout": "Pre-registered primary symptom outcome, analysed both unadjusted and adjusted for guessed allocation, with the guess-accuracy distribution reported.", "critical_control": "The allocation-guess data themselves; a trial that does not report them reproduces the gap this review identifies rather than closing it.", "falsifying_result": "No drug-comparator difference among participants who guessed correctly at chance level would place SC2 below its current ceiling and would trigger the rubric's first falsification pattern.", "supporting_result": "A drug effect surviving adjustment for guessed allocation would cross Δ for SC2 and would remove the largest single objection to the efficacy clause." }, { "name": "Stratification of SSRI response by an independently measured baseline serotonergic index", "experiment": "Prospective cohort within a randomised SSRI trial in which baseline serotonergic function is measured independently - for example by a challenge paradigm of the kind used in C6 - before randomisation, with response analysed by baseline stratum.", "readout": "Pre-registered interaction between baseline serotonergic index and drug-placebo difference.", "critical_control": "Blinding of the baseline index to treatment allocation and of the outcome raters to the index, and a pre-registered stratum definition, so the strata cannot be fitted after outcomes are known (pitfall 22).", "falsifying_result": "Equal benefit regardless of baseline serotonergic function would refute the deficit-correction clause directly; SC3 would move from 'not demonstrated' to 'shown not to be'.", "supporting_result": "Benefit concentrated in a pre-defined low-function stratum would be the first evidence that SSRIs correct a deficit rather than displacing a system that was not deficient, and would cross Δ for SC3." } ], "knowledge_gaps": [ { "name": "No validated in vivo measure of synaptic serotonin in untreated depression", "statement": "There is no measure of synaptic serotonin availability in living untreated patients that is validated, specific and scalable; the nearest available index is release capacity inferred from radioligand displacement in samples of a few tens of people.", "relevance": "Without it, SC1's premise cannot be tested directly and SC3's stratification experiment cannot be run, so both are confined to Γ regardless of how much further observational work accumulates." }, { "name": "Specificity of tryptophan depletion", "statement": "It is not established that acute tryptophan depletion lowers brain serotonin specifically, as against altering amino-acid balance, neurotrophic signalling and cerebrovascular parameters at the same time.", "relevance": "This is the single constraint holding SC4 at Δ rather than higher, and it is resolvable with a matched non-depleting control arm." }, { "name": "Blinding integrity has never been measured in the SSRI trial base", "statement": "No SSRI trial in the syntheses examined here reports allocation-guess data, so the magnitude of functional unblinding is unknown rather than known to be small.", "relevance": "It is the reason SC2 cannot cross Δ despite resting on the largest randomised evidence base in psychiatry, and it is cheap to close in any new trial." }, { "name": "The deficit-correction question has never been posed as an experiment", "statement": "No study has stratified antidepressant response by an independently measured baseline serotonergic index.", "relevance": "SC3 is the clause that gives the hypothesis its distinguishing content, and it remains untested rather than refuted." } ], "review_metadata": { "review_date": "2026-09-27", "reviewer": "Red-team synthesis: Claude (Anthropic), independent model, 2026-09-27. Input grading under review: 'HSEF Review Agent v5.0' (OpenAI Codex environment), schema 5.4, 2026-09-27, archived unaltered at sources/A_v5.4_grading/.", "evidence_base_note": "Canonical evidence base. Seventeen sources: the eight of the input grading, four of which required identifier correction and one of which was a composite of three records, plus nine added by the omission audit in both directions - the published critique of and reply to the umbrella review, the two large null genetic studies, the challenge-PET release-capacity study, the active-placebo Cochrane review, the patient-level severity re-analysis, a belief-transmission survey for the divergence basis, and an interferon incidence meta-analysis for the tournament.", "literature_tools_available": true, "literature_tools_note": "PubMed metadata and PMC full text were reachable and were used for every ledger row; ClinicalTrials.gov was reachable and was used for the momentum artifact. Full text was read for sources 1, 2, 10 and 14; source 3 was read in the accessible portion only; the remaining thirteen were verified at abstract and metadata level, the paywalled ones being sources 4, 5, 6, 13 and 17.", "skill_version": "5.4", "validator_run": "pass", "validator_warnings_addressed": "See final/validation.txt: 0 fail, 0 warn. The corpus-modal M/S/D warning raised against the input grading no longer applies: Stability is Stable, with the reason recorded. Post-verification corrections of 2026-09-27 (rodent clause removed from SC1's support, divergence reference class stated, lay summary moved, HSEF heading standardised) are recorded in redteam/change-log.md.", "consensus_consistency_audit": "2026-10-09; supplementary provenance/source reconciliation; original grading retained; prior grades visible." }, "is_calibration_entry": { "value": false, "entry_role": "not_calibration", "blind_graded": null, "completed_blinded_calibration": false, "expected_band_sealed_at": "", "target_sha256": "", "target_authorship": "not applicable", "target_author_saw_review": null, "future_run_status": "not prepared", "unblinded_reason": "This is a revision of an existing grading, not a calibration entry. The prior level was supplied to this pass in its brief, so it could not be graded blind; that is recorded in the change record." }, "upper_ladder_check": { "final_level_below_zeta": true, "equivalents_considered": [ { "kind": "mendelian_randomization", "available": true, "why_not_sufficient": "The obvious instrument for the serotonin system - 5-HTTLPR and the historical candidate-gene set - is null in the two largest and best-powered analyses available (C7, C8). A null instrument cannot carry the claim upward, and because it is also a weak instrument for synaptic serotonin it cannot be read as refuting it either." }, { "kind": "natural_experiment", "available": false, "why_not_sufficient": "There is no population-scale natural experiment that alters serotonergic transmission cleanly and independently of the psychosocial and medical determinants of depression." }, { "kind": "dose_response_across_populations", "available": true, "why_not_sufficient": "SSRI dose-response across populations is flat above the therapeutic range, and in any case indexes drug exposure rather than the serotonergic state the hypothesis is about." }, { "kind": "withdrawal_rechallenge", "available": true, "why_not_sufficient": "The strongest form of this design in the field is the depletion-reversal paradigm, and it is counted - it is what carries SC4 to Δ. It does not carry the graded claim further because withdrawal of serotonin from a drug-elevated state cannot show that the pre-drug state was deficient, and antidepressant discontinuation studies are confounded by withdrawal effects." }, { "kind": "therapeutic_perturbation_hard_endpoint", "available": true, "why_not_sufficient": "SSRI trials perturb the system therapeutically against a symptom endpoint, but with no comparator matched for acute subjective effect (C11, C12) and with the mechanism unidentified, so they bear on SC2 rather than on the causal claim." } ], "convergence_present": false, "cap_reapplied_to_convergent_set": false }, "independence_basis": { "required": false, "lines": [], "shared_failure_mode_checked": null, "note": "Not required: no level at Ζ or above is assigned. Recorded for the next update: were SC4 ever advanced to Ζ, the depletion-reversal studies in drug-free remitted patients and in medicated remitted patients would not be two independent lines, because a single systematic error in the depletion procedure's specificity would defeat both." }, "consensus_validation": { "completed": true, "status": "documented_historical_discovery_and_reconciliation", "provider": "Consensus", "provider_mode": "Historical browser/connector use as recorded in the source artifacts", "local_audit_date": "2026-10-09", "primary_comparison_count": null, "reported_usage": [], "grade_changed": false, "score_before": { "hsef_level": "Γ", "hsef_descriptor": "Mechanistically plausible, partial system support", "confidence": "Moderate", "confidence_rationale": "Evidence density is high for the efficacy clause and moderate for the serotonin clause, but reproducibility in the serotonin literature is demonstrably poor: the candidate-gene and gene-by-stress programme collapsed in the largest samples (C7, C8), the imaging findings are inconsistent across reviews and confounded by medication history (C1), the depletion literature is heterogeneous in protocol and partly concentrated in overlapping groups (C3, C4), and the single direct measure of release capacity is unreplicated with 17 patients (C6). That is the framework's description of Moderate, not High. The input grading's High rested on a base of eight abstract-only sources of which four carried identifiers pointing at unrelated papers.", "rests_on_non_peer_reviewed_work": false, "rationale": "Weakest-link over SC1=Γ, SC2=Γ, SC3=Γ, SC4=Δ gives Γ. The mechanism is plausible and has partial human support - an unblinded challenge study, the pharmacology of the drugs themselves, and one positive human mediator manipulation; what has not been shown is the endogenous, disease-relevant causal dependency the claim asserts - that a serotonin deficiency exists in depression and that correcting it is how treatment works." }, "score_after": { "hsef_level": "Γ", "hsef_descriptor": "Mechanistically plausible, partial system support", "confidence": "Moderate", "confidence_rationale": "Evidence density is high for the efficacy clause and moderate for the serotonin clause, but reproducibility in the serotonin literature is demonstrably poor: the candidate-gene and gene-by-stress programme collapsed in the largest samples (C7, C8), the imaging findings are inconsistent across reviews and confounded by medication history (C1), the depletion literature is heterogeneous in protocol and partly concentrated in overlapping groups (C3, C4), and the single direct measure of release capacity is unreplicated with 17 patients (C6). That is the framework's description of Moderate, not High. The input grading's High rested on a base of eight abstract-only sources of which four carried identifiers pointing at unrelated papers.", "rests_on_non_peer_reviewed_work": false, "rationale": "Weakest-link over SC1=Γ, SC2=Γ, SC3=Γ, SC4=Δ gives Γ. The mechanism is plausible and has partial human support - an unblinded challenge study, the pharmacology of the drugs themselves, and one positive human mediator manipulation; what has not been shown is the endogenous, disease-relevant causal dependency the claim asserts - that a serotonin deficiency exists in depression and that correcting it is how treatment works." }, "independent_blinded_audit": false, "raw_receipts": [ { "path": "deliverables\\prepublication-enrichment-2026-10-05\\website-series\\mdd-serotonin\\consensus-browser-links.json", "sha256": "cc2c4e6eb51d4eb8dbf79494d1c9b0381529ffb8f013eb175e28630a5b7f3fe0" }, { "path": "deliverables\\prepublication-enrichment-2026-10-05\\website-series\\mdd-serotonin\\consensus-browser.txt", "sha256": "ccc4d01cd433871b4d98c4a20673ff21ead4c7fe288daef50d9afc35b50a894b" }, { "path": "deliverables\\prepublication-enrichment-2026-10-05\\website-series\\mdd-serotonin\\consensus-targeted-check.txt", "sha256": "d630080a417e70beeeeb605c4a5b6ad8df92321db85f5905fe88cd2854eefd6f" } ], "limitations": "This verifies documented historical use and links the record to the final edition. It adds no primary-source, full-text, independence or verification credit. Original access remains limited to the source-specific record.", "existing_primary_reconciliation": { "slug": "mdd-serotonin", "consensus_used": true, "rawproof": [ "deliverables/prepublication-enrichment-2026-10-05/website-series/mdd-serotonin/consensus-browser.txt", "deliverables/prepublication-enrichment-2026-10-05/website-series/mdd-serotonin/consensus-targeted-check.txt", "deliverables/prepublication-enrichment-2026-10-05/website-series/mdd-serotonin/consensus-browser-links.json" ], "reconciliation_existing": "Yes; 7 distinct primary identifiers, abstract/metadata checks documented; excludes unrelated PMID from verification.", "primary_sources_matched": [ "2184795", "7944875", "12869766", "15289275", "19755572", "30845820", "36635177" ], "limitations": "No independently readable body verified; update explicitly avoids padding with meta-analyses." } } }